|
TCMBANKIN000080 |
Deoxycholic Acid |
SCHEMBL11962424; deoxycholic acid; Deoxycholicacid; deoxycholicacid; AKOS015965182; AC-20221 |
C24H40O4 |
392.57 |
CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C |
|
TCMBANKIN000088 |
cryptotanshinone |
NCI60_031208; CTS; 4733-35-1; A822990; C19H22O3; ZINC02109876; SMR000387041; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[8,7-g][1]benzoxole-10,11-dione; (1R)-1,6,6-trimethyl-2,3a,7,8,9,11a-hexahydro-1H-naphtho[1,2-g][1]benzofuran-10,11-dione; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[8,7-g]benzofuran-10,11-quinone; (1R)-1,6,6-trimethyl-2,3a,7,8,9,11a-hexahydro-1H-naphtho[1,2-g]benzofuran-10,11-dione; NCGC00163650-01; BB_NC-1574; Phenanthro[1,2-b]furan-10,11-dione, 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (1R)-; MolPort-006-823-903; (1R)-1,6,6-trimethyl-1,2,3a,6,7,8,9,11a-octahydrophenanthro[1,2-b]furan-10,11-dione; MLS001049002; 35825-57-1; DTXSID0044072; (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[8,7-g]benzofuran-10,11-dione; (-)-Cryptotanshinone; Phenanthro(1,2-b)furan-10,11-dione, 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (R)-; SPECTRUM1505812 |
C19H20O3 |
296.36 |
CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C |
|
TCMBANKIN000383 |
Euphol |
CHEMBL465181; (3S,5R,10S,13S,14S,17S)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; ST24047202; AIDS-064689; ZINC4097719; FT-0698509; AIDS064689; CHEBI:4940; AKOS016010616; Euphol (6CI); AC1L9BGD; (3S,5R,10S,13S,14S)-17-((R)-1,5-Dimethyl-hex-4-enyl)-4,4,10,13,14-pentamethyl-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; SCHEMBL541497; BG01135940; (20R)-(+)-triucalla-8,24-diene-3beta-ol; AK120346; euphol; (3S,5R,10S,13S,14S,17S)-17-[(1R)-1,5-dimethylhex-4-enyl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; (3beta,13alpha,14beta,17alpha)-Lanosta-8,24-dien-3-ol; Lanosta-8,24-dien-3-ol, (3.beta.,13.alpha.,14.beta.,17.alpha.)-; Euphadienol; (+)-Euphol; (s)-euphol; (+)-alpha-Euphol; AJ-48007; alpha-Euphol; Eupha-8,24-dienol; C08624; 514-47-6; LMPR0106090002; KB-277032; 13alpha,14beta,17betaH-Lanosta-8,24-dien-3beta-ol (8CI); 7162AB |
C30H50O |
426.72 |
CC(CCC=C(C)C)C1CCC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)O)C)C)C |
|
TCMBANKIN000962 |
campesterol |
campesterol ; FT-0082089; Augelicincampesterol; (24R)-5-Ergosten-3; (1R,3AS,3BR,9AS,9BS,11AR)-1-[(2R,5R)-5,6-DIMETHYLHEPTAN-2-YL]-9A,11A-DIMETHYL-1H,2H,3H,3AH,3BH,4H,5H,5AH,6H,9H,9BH,10H,11H-CYCLOPENTA[A]PHENANTHREN-7-OL; A-ol; 24(R)-Ergost-5-en-3beta-ol; 24alpha-Methyl-5-cholesten-3beta-ol; AK307302; SC-66911; (8R,9S,10S,13R,14S,17R)-17-((2R,5R)-5,6-Dimethylheptan-2-yl)-10,13-dimethyl-4,5,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; AKOS027320474; MFCD00010475; Campesterin; MolPort-035-882-175 |
C28H48O |
400.68 |
CC(C)C(C)CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
|
TCMBANKIN001013 |
fernenol |
C16958; CHEBI:80823; 4966-00-1; Fernenol |
C30H50O |
426.72 |
CC(C)C1CCC2C1(CCC3(C2(CC=C4C3CCC5C4(CCC(C5(C)C)O)C)C)C)C |
|
TCMBANKIN001029 |
Penconazol |
|
C13H15Cl2N3 |
284.18 |
|
|
TCMBANKIN001613 |
LC 5504 |
15,16-Diepxoylabdane-14-en-7-one; 132922-55-5; Dispiro(furan-3(2H),2'(5'H)-furan-5',1''(2''H)-naphthalen)-3''(4''H)-one, 3',4',4''a,5'',6'',7'',8'',8''a-octahydro-2'',5'',5'',8''a-tetramethyl-, (1''R-(1''alpha(R*),2''alpha,4''aalpha,8''abeta))- |
C20H30O3 |
318.45 |
CC1C(=O)CC2C(CCCC2(C13CCC4(O3)COC=C4)C)(C)C |
|
TCMBANKIN002037 |
(3S,4S,5R,10S,13R,14R,17R)-4,10,13,14-tetramethyl-17-((R)-6-methyl-5-methyleneheptan-2-yl)-2,3,4,5,6,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
|
|
424.78 |
|
|
TCMBANKIN002210 |
4,24-methyllophenol |
|
C29H50O |
414.71 |
|
|
TCMBANKIN002233 |
(8R)-3-oxo-8-hydroxy-polypoda -13E,17E,21-triene |
|
|
442.8 |
|
|
TCMBANKIN002312 |
(3Z,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5,8a-dimethyl-2-methylene-5-methylol-decalin-1-yl]ethylidene]-4-hydroxy-tetrahydrofuran-2-one |
(3Z,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-decalinyl]ethylidene]-4-hydroxy-2-tetrahydrofuranone; (3Z,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]ethylidene]-4-hydroxy-tetrahydrofuran-2-one; (3Z,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxy-oxolan-2-one; (3Z,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one |
C20H30O5 |
350.45 |
|
|
TCMBANKIN002424 |
fischeriana B_qt |
|
C26H36O9 |
492.56 |
|
|
TCMBANKIN002465 |
(2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one |
BB_NC-1001; (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-chromanone; ZINC00001785 |
C15H12O5 |
272.25 |
|
|
TCMBANKIN002496 |
poriferasta-7,22E-dien-3beta-ol |
(3S,5S,9R,10S,13R,14R,17R)-17-[(E,2R,5R)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5S,9R,10S,13R,14R,17R)-17-[(E,2R,5R)-5-ethyl-6-methyl-hept-3-en-2-yl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; LMST01040140; (3S,5S,9R,10S,13R,14R,17R)-17-[(E,1R,4R)-4-ethyl-1,5-dimethyl-hex-2-enyl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5S,9R,10S,13R,14R,17R)-17-[(E,1R,4R)-4-ethyl-1,5-dimethylhex-2-enyl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C29H48O |
412.69 |
CCC(C=CC(C)C1CCC2C1(CCC3C2=CCC4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN002539 |
pelargonidin |
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-1lambda-chromen-1-ylium; Pelargonidin-3,5-diglucoside_qt; 7690-51-9; C05904; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromenylium; XVFMGWDSJLBXDZ-UHFFFAOYSA-O; 3,4',5,7-Tetrahydroxyflavylium; anthocyanidin; pelargonidin 3,5-di-O-glycoside_qt; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-1-benzopyrylium; CHEBI:25863; 2-(4-hydroxyphenyl)chromenylium-3,5,7-triol; 2-(4-hydroxyphenyl)-1-benzopyrylium-3,5,7-triol; LMPK12010003; CHEMBL591036; pelargonidin-3-O-glucoside_qt; pelargonidin-3,5-di-O-glucoside_qt; BDBM50121994; CHEMBL1197905; A806724; BDBM50326998; 1-Benzopyrylium, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-; SCHEMBL20592; 134-04-3 (chloride); ZINC391840; Pelargonidin; AC1L9A0P; ZB012073 |
C15H11O5+ |
271.24 g/mol |
C1=CC(=CC=C1C2=[O+]C3=CC(=CC(=C3C=C2O)O)O)O |
|
TCMBANKIN002631 |
(8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
(8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methyl-hept-3-en-2-yl]-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (8S,9S,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethylhex-2-enyl]-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (8S,9S,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethyl-hex-2-enyl]-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
C29H50O |
414.71 |
|
|
TCMBANKIN002899 |
isoarborinol |
|
C30H50O |
426.72 |
CC(C)C1CCC2C1(CCC3(C2(CC=C4C3CCC5C4(CCC(C5(C)C)O)C)C)C)C |
|
TCMBANKIN002903 |
delta 5-Pregnenetriol |
(3S,8R,9S,10R,13S,14S,17R)-17-(1-hydroxyethyl)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol; 903-67-3; 5-Pregnene-3beta,17alpha,20alpha-triol; Pregn-5-ene-3,17,20-triol, (3beta,20S)-; Pregn-5-ene-3beta,17alpha,20alpha-triol |
C21H34O3 |
334.49 |
CC(C1(CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)O)O |
|
TCMBANKIN003113 |
(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5S)-5-ethyl-6-methylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
(3S,8S,9S,10R,13R,14S,17R)-17-[(1R,4S)-4-ethyl-1,5-dimethylhex-5-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5S)-5-ethyl-6-methyl-hept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(1R,4S)-4-ethyl-1,5-dimethyl-hex-5-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C29H48O |
412.69 |
|
|
TCMBANKIN003248 |
(2R,4aS,10aR)-7-isopropyl-2,4a-dimethyl-1-methylene-4,9,10,10a-tetrahydro-3H-phenanthren-2-ol |
(2R,4aS,10aR)-2,4a-dimethyl-1-methylidene-7-propan-2-yl-4,9,10,10a-tetrahydro-3H-phenanthren-2-ol |
|
284.48 |
|
|
TCMBANKIN003665 |
evoden |
|
|
|
C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O |
|
TCMBANKIN003703 |
paryriogenin I |
|
|
422.71 |
|
|
TCMBANKIN003804 |
Adiantone |
adiantone |
C29H48O |
412.7 g/mol |
CC(=O)C1CCC2(C1CCC3(C2CCC4C3(CCC5C4(CCCC5(C)C)C)C)C)C |
|
TCMBANKIN004363 |
22-Stigmasten-3-one |
|
C29H48O |
412.7 g/mol |
CCC(C=CC(C)C1CCC2C1(CCC3C2CCC4C3(CCC(=O)C4)C)C)C(C)C |
|
TCMBANKIN004387 |
pomiferin |
|
C25H24O6 |
420.5 g/mol |
CC(=CCC1=C2C(=C3C(=C1O)C(=O)C(=CO3)C4=CC(=C(C=C4)O)O)C=CC(O2)(C)C)C |
|
TCMBANKIN004388 |
macrostemonoside d_qt |
macrostemonoside a_qt |
|
400.71 |
|
|
TCMBANKIN004445 |
Δ7,22,25-triene-3-ol |
Δ7,16,25,26-stigmastatrienol-3-O-glucoside_qt |
|
410.75 |
|
|
TCMBANKIN004467 |
[(1S,3R,4R,4aS,8aS)-3,4a,8,8-tetramethyl-5'-oxo-spiro[decalin-4,2'-tetrahydrofuran]-1-yl] acetate |
[(1S,3R,4R,4aS,8aS)-3,4a,8,8-tetramethyl-5'-oxospiro[2,3,5,6,7,8a-hexahydro-1H-naphthalene-4,2'-oxolane]-1-yl] acetate; acetic acid [(1S,3R,4R,4aS,8aS)-5'-keto-3,4a,8,8-tetramethyl-spiro[decalin-4,2'-tetrahydrofuran]-1-yl] ester; acetic acid [(1S,3R,4R,4aS,8aS)-3,4a,8,8-tetramethyl-5'-oxo-1-spiro[decalin-4,2'-tetrahydrofuran]yl] ester; [(1S,3R,4R,4aS,8aS)-3,4a,8,8-tetramethyl-5'-oxo-spiro[2,3,5,6,7,8a-hexahydro-1H-naphthalene-4,2'-oxolane]-1-yl] ethanoate |
|
322.49 |
|
|
TCMBANKIN004484 |
vittadinoside_qt |
|
|
412.77 |
|
|
TCMBANKIN004585 |
14-methyl-alpha-sitosterol |
|
|
440.83 |
|
|
TCMBANKIN004652 |
2-[(1R)-2,2,3-trimethyl-1-cyclopent-3-enyl]ethanal |
ZINC01063075; 2-[(1R)-2,2,3-trimethyl-1-cyclopent-3-enyl]acetaldehyde |
C10H16O |
152.23 |
|
|
TCMBANKIN004943 |
Epibetulinic acid |
AIDS-107572; 3-Hydroxylup-20(29)-en-28-oic acid,(3.alpha.); AIDS107572 |
C30H48O3 |
456.7 |
CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)C(=O)O |
|
TCMBANKIN005001 |
Rosmarinate |
537-15-5; InChI=1/C18H16O8/c19-12-4-1-10(7-14(12)21)3-6-17(23)26-16(18(24)25)9-11-2-5-13(20)15(22)8-11/h1-8,16,19-22H,9H2,(H,24,25)/b6-3; (2S)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)acryloyl]oxy-propionic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxypropanoic acid; C01850; 3-(3,4-Dihydroxy-phenyl)-acrylic acid 1-carboxy-2-(3,4-dihydroxy-phenyl)-ethyl ester; benzenepropanoic acid, alpha-[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-3,4-dihydroxy-; (2S)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)-1-oxoprop-2-enoxy]propanoic acid; 3-(3,4-dihydroxyphenyl)-2-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}propanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; CHEBI:17226 |
C18H16O8 |
360.31 |
C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O |
|
TCMBANKIN005413 |
(3S,5S,9R,10S,13R,14R,17R)-17-[(2R,3E,5S)-5-ethyl-6-methylhepta-3,6-dien-2-yl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
(3S,5S,9R,10S,13R,14R,17R)-17-[(2R,3E,5S)-5-ethyl-6-methyl-hepta-3,6-dien-2-yl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5S,9R,10S,13R,14R,17R)-17-[(1R,2E,4S)-4-ethyl-1,5-dimethyl-hexa-2,5-dienyl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5S,9R,10S,13R,14R,17R)-17-[(1R,2E,4S)-4-ethyl-1,5-dimethylhexa-2,5-dienyl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C29H46O |
410.67 |
|
|
TCMBANKIN005420 |
periplocin_qt |
|
|
390.57 |
|
|
TCMBANKIN005465 |
1-[(5R,8R,9S,10S,12R,13S,14S,17S)-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone |
|
|
318.55 |
|
|
TCMBANKIN005486 |
α-amyrenonol |
|
|
424.78 |
|
|
TCMBANKIN005814 |
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol |
(3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol |
|
396.72 |
|
|
TCMBANKIN006029 |
polygosides E_qt |
polygosides C_qt; polygosides D_qt |
|
412.67 |
|
|
TCMBANKIN006040 |
Rubrosterone |
rubrosterone |
C19H26O5 |
334.41 |
CC12CCC3C(=CC(=O)C4C3(CC(C(C4)O)O)C)C1(CCC2=O)O |
|
TCMBANKIN006050 |
parkeol |
|
C30H50O |
426.7 g/mol |
CC(CCC=C(C)C)C1CCC2(C1(CC=C3C2CCC4C3(CCC(C4(C)C)O)C)C)C |
|
TCMBANKIN006198 |
zymostrol |
CHEBI:18252; EINECS 204-880-9; LMST01010066; 128-33-6; (3S,5S,10S,13R,14R,17R)-17-[(1R)-1,5-dimethylhex-4-enyl]-10,13-dimethyl-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5S,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; C05437; 5-alpha-Cholesta-8,24-dien-3-beta-ol; delta8,24-Cholestadien-3beta-ol; Zymosterol; 5alpha-Cholesta-8,24-dien-3beta-ol |
C27H44O |
384.64 |
CC(CCC=C(C)C)C1CCC2C1(CCC3=C2CCC4C3(CCC(C4)O)C)C |
|
TCMBANKIN006312 |
10α-cucurbita-5,24-diene-3β-ol |
|
|
426.8 |
|
|
TCMBANKIN006523 |
(3S,8S,9S,10R,13R,14S,17R)-17-[(1S,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
(3S,8S,9S,10R,13R,14S,17R)-17-[(2S,5R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(1S,4R)-4-ethyl-1,5-dimethyl-hexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(2S,5R)-5-ethyl-6-methyl-heptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C35H60O6 |
576.85 |
|
|
TCMBANKIN006865 |
lanost-8-en-3beta-ol |
24,25-Dihydrolanosterol; C05109; LMST01010087; CHEBI:28113; (3S,5R,10S,13R,14R,17R)-17-[(1R)-1,5-dimethylhexyl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol |
C30H52O |
428.73 |
CC(C)CCCC(C)C1CCC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)O)C)C)C |
|
TCMBANKIN007023 |
stigmast-7-enol |
|
C29H46O |
410.67 |
CCC(CCC(C)C1CCC2C1(CCC3C2=CCC4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN007152 |
ELTANOLONE |
Eltanolonum [INN-Latin]; Pregnanolone; 3.alpha.,5.beta.-Epimeric pregnanolone; Pregnanolone II; CHEBI:1712; 3.alpha.-Hydroxy-5.beta.-tetrahydroprogesterone; Eltanolone [INN]; 5.beta.-Pregnan-20-one, 3.alpha.-hydroxy-; WLN: L E5 B666TJ A1 E1 FV1 OQ; 3alpha-Hydroxy-5beta-tetrahydroprogesterone; 5beta-Pregnan-20-one, 3alpha-hydroxy- (8CI); NSC 82867; BRN 4785659; SKF 6455; (3alpha,5beta)-3-hydroxypregnan-20-one; 3alpha-Hydroxy-5beta-pregnan-20-one; 5beta-Pregnan-3alpha-ol-20-one; 3alpha,5beta-Epimeric pregnanolone; 3-alpha-Hydroxy-5-beta-pregnan-20-one; Pregnan-20-one, 3-hydroxy-, (3alpha,5beta)-; NSC82867; 128-20-1; 1-[(3R,5R,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone; 3.alpha.-Hydroxy-5.beta.-pregnan-20-one; Pregnan-3alpha-ol-20-one; Eltanolona [INN-Spanish]; 5-beta-Pregnan-20-one, 3-alpha-hydroxy- |
C21H34O2 |
318.49 |
CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C |
|
TCMBANKIN007154 |
(3Z)-3-[2-[(1R,2S,4aS,8aS)-5,5,8a-trimethylspiro[decalin-2,2'-oxirane]-1-yl]ethylidene]tetrahydrofuran-2-one |
(3Z)-3-[2-[(1R,2S,4aS,8aS)-5,5,8a-trimethyl-1-spiro[decalin-2,2'-oxirane]yl]ethylidene]-2-tetrahydrofuranone; (3Z)-3-[2-[(1R,2S,4aS,8aS)-5,5,8a-trimethylspiro[3,4,4a,6,7,8-hexahydro-1H-naphthalene-2,2'-oxirane]-1-yl]ethylidene]oxolan-2-one |
C27H30O14 |
578.52 |
|
|
TCMBANKIN007224 |
NSC63551 |
(5R,8R,9S,10S,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethyl-hex-2-enyl]-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; (5R,8R,9S,10S,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methyl-hept-3-en-2-yl]-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; (5R,8R,9S,10S,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; 4736-55-4; (5R,8R,9S,10S,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethylhex-2-enyl]-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one |
C29H48O |
412.69 |
CCC(C=CC(C)C1CCC2C1(CCC3C2CCC4C3(CCC(=O)C4)C)C)C(C)C |
|
TCMBANKIN007258 |
Yamogenin |
WQLVFSAGQJTQCK-CAKNJAFZSA-N; (25S)-spirost-5-en-3beta-ol; NSC 226132; LMST01080045; AC1L9BVW; AC-8895; S00020; (2R,5'S)-5'-tetramethylspiro[[?]-2,2'-tetrahydropyran]ol; Jamogenin; Neodiosgenin; AKOS025402417; CHEBI:10086; Spirost-5-en-3-ol, (3beta,25S)-; SCHEMBL6040875; CHEMBL400807; C08918; yamogenin; ZINC8234229; 512-06-1; 25-epi-Diosgenin |
C27H42O3 |
414.62 |
CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)O)C)C)C)OC1 |
|
TCMBANKIN007637 |
(1S,5S)-1-isopropyl-4-methylenebicyclo[3.1.0]hexane |
(1S,5S)-1-isopropyl-4-methylene-bicyclo[3.1.0]hexane; (1S,5S)-4-methylidene-1-propan-2-ylbicyclo[3.1.0]hexane; (1S,5S)-4-methylidene-1-propan-2-yl-bicyclo[3.1.0]hexane |
C10H16 |
136.23 g/mol |
CC(C)C12CCC(=C)C1C2 |
|
TCMBANKIN007694 |
p-mentha-1(7)-dien-8-ol |
|
|
152.26 |
|
|
TCMBANKIN007926 |
spinastenol |
|
|
412.77 |
|
|
TCMBANKIN007988 |
(3S,5S,9R,10S,13R,14R,17R)-17-[(2R,5S)-5-ethyl-6-methylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
(3S,5S,9R,10S,13R,14R,17R)-17-[(1R,4S)-4-ethyl-1,5-dimethyl-hex-5-enyl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5S,9R,10S,13R,14R,17R)-17-[(2R,5S)-5-ethyl-6-methyl-hept-6-en-2-yl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5S,9R,10S,13R,14R,17R)-17-[(1R,4S)-4-ethyl-1,5-dimethylhex-5-enyl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
|
412.77 |
|
|
TCMBANKIN008024 |
21-Hydroxy-30-norhopan-22-one |
21-hydroxy-30-norhopan-22-one; 1-[(3R,3aR,5bR,11aS,13aR)-3-hydroxy-5a,5b,8,8,11a,13b-hexamethyl-2,3a,4,5,6,7,7a,9,10,11,11b,12,13,13a-tetradecahydro-1H-cyclopenta[a]chrysen-3-yl]ethanone; AC1NSWNO |
C29H48O2 |
428.77 |
CC(=O)C1(CCC2(C1CCC3(C2CCC4C3(CCC5C4(CCCC5(C)C)C)C)C)C)O |
|
TCMBANKIN008033 |
macrostemonoside f_qt |
|
|
416.71 |
|
|
TCMBANKIN008366 |
2- methyl-5-(5 ' -hydroxy-1 ' ,5 ' -dimethyl-3 ' -hexenyl)phenol |
|
|
232.4 |
|
|
TCMBANKIN008602 |
Cholanoic acid |
5.beta.-Cholanic acid; CHEBI:36238; Cholan-24-oic acid, (5beta)- (9CI); LMST04010441; Cholan-24-oic acid, (5.beta.)-; (4R)-4-[(5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; NSC18161; (4R)-4-[(5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; Ursocholanic acid; 5beta-Cholanoic acid; 5beta-Cholan-24-oic acid (8CI); NSC 18161; Androstane-17-butanoic acid, gamma-methyl-, (5beta,17beta)-; 5beta-Cholan-24-oic Acid; 5.beta.-Cholan-24-oic acid; L 596205-0; 5beta-Cholanic acid; Androstane-17-butanoic acid, .gamma.-methyl-, (5.beta.,17.beta.)-; (5beta)-cholan-24-oic acid; 546-18-9; 5.beta.-Cholanoic acid; (5beta,17beta)-gamma-methylandrostane-17-butanoic acid |
C24H40O2 |
360.57 |
CC(CCC(=O)O)C1CCC2C1(CCC3C2CCC4C3(CCCC4)C)C |
|
TCMBANKIN008667 |
21-O-Methyl-5,14-pregndiene-3β,14β,17β,21-tetrol-20-one |
|
|
362.56 |
|
|
TCMBANKIN008854 |
(13E,17E,21E)-8-hydroxypolypodo-13,17,21-trien-3-one |
|
|
440.83 |
|
|
TCMBANKIN008871 |
abricin |
|
C27H44O2 |
400.64 |
|
|
TCMBANKIN008878 |
Anemarsaponin B_qt |
|
C45H74O18 |
903.06 |
|
|
TCMBANKIN009220 |
epimansumbinol |
|
|
316.58 |
|
|
TCMBANKIN009405 |
31-norlanost-9(11)-enol |
|
|
414.79 |
|
|
TCMBANKIN009412 |
rosasterol |
|
|
414.79 |
|
|
TCMBANKIN009441 |
4α,14α-dimethyl-5α-ergosta-7,9(11),24(28)-trien-3β-ol |
|
|
424.78 |
|
|
TCMBANKIN009488 |
pinocarvone |
|
C10H14O |
150.22 |
CC1(C2CC1C(=C)C(=O)C2)C |
|
TCMBANKIN009557 |
lathosterol |
cholest-7-en-3beta-ol; delta(sup 7)-Cholestenol; (3S,5S,9R,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; ST5331314; 5alpha-Cholest-7-en-3beta-ol; (3-beta,5-alpha)-Cholest-7-en-3-ol; 5-alpha-Cholest-7-en-3-beta-ol; gamma-Cholesterol; C01189; CHEBI:17168; Cholest-7-en-3-ol, (3-beta,5-alpha)- (9CI); Cholesterin [German]; LMST01010089; (3S,5S,9R,10S,13R,14R,17R)-17-[(1R)-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 7-Cholesten-3-beta-ol |
C27H46O |
386.65 |
CC(C)CCCC(C)C1CCC2C1(CCC3C2=CCC4C3(CCC(C4)O)C)C |
|
TCMBANKIN009752 |
ZINC04081604 |
(8S,9S,10R,13S,14R,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (8S,9S,10R,13S,14R,17S)-17-ethanoyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
C21H30O2 |
314.46 |
|
|
TCMBANKIN009926 |
ergosta-7,22-dien-3-one |
(22E,24R)-ergosta-7,22-dien-3 β-one; Ergosta-7,22-dien-3-one |
C28H44O |
396.6 g/mol |
CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2=CCC4C3(CCC(=O)C4)C)C |
|
TCMBANKIN010351 |
Glycoside K_qt |
Glycoside H1_qt |
|
318.55 |
|
|
TCMBANKIN010674 |
shionone |
(1R,4aS,4bS,6aS,8R,10aR,10bS,12aS)-1,4b,6a,8,10a,12a-hexamethyl-8-(4-methylpent-3-en-1-yl)hexadecahydrochrysen-2(1H)-one; UNII-BT0AMD31UB; Shionone; 10376-48-4; N2225; CHEBI:63459; BT0AMD31UB; Shionon; AKOS030573546; 2(1H)-Chrysenone,hexadecahydro-1,4b,6a,8,10a,12a-hexamethyl-8-(4-methyl-3-penten-1-yl)-,(1R,4aS,4bS,6aS,8R,10aR,10bS,12aS)-; D:A-Friedo-18,19-secolup-19-en-3-one; 376S484; C17966; ZINC6037228; AK608266; MolPort-020-005-764; FT-0697220; Ambap10376-48-4 |
C30H50O |
426.72 |
CC1C(=O)CCC2C1(CCC3C2(CCC4(C3(CCC(C4)(C)CCC=C(C)C)C)C)C)C |
|
TCMBANKIN010855 |
4alpha,24-dimethylcholesta-7,24-dienol |
|
C29H48O |
412.7 g/mol |
CC1CCCC2(C1CC=C3C2CCC4(C3CCC4C(C)CCC(=C(C)CO)C)C)C |
|
TCMBANKIN010884 |
Spirostan-3-ol, (3alpha,5alpha,25S)- |
75172-34-8 |
C27H44O3 |
416.64 |
CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)O)C)C)C)OC1 |
|
TCMBANKIN010953 |
stigmast-7-enol-glucoside_qt |
|
|
414.79 |
|
|
TCMBANKIN011625 |
ergosta-7,22-diene-3β-ol |
(22e,24r)-ergosta-7,22-dien-3beta-ol |
C28H46O |
398.7 g/mol |
CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2=CCC4C3(CCC(C4)O)C)C |
|
TCMBANKIN011650 |
Siegesmethyletheric acid |
siegesmethylethericacid; siegesmethyletheric acid |
|
334.55 |
CC12CCCC(C1CCC34C2CCC(C3)C(C4)COC)(C)C(=O)O |
|
TCMBANKIN011783 |
(8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-7-one |
(8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methyl-heptan-2-yl]-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-7-one; (8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethyl-hexyl]-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-7-one; (8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-7-one |
C29H46O |
410.67 |
|
|
TCMBANKIN012035 |
Stigmasta-5,22-dien-3-beta-yl acetate |
EINECS 225-082-7; [(3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; acetic acid [(3S,8S,9S,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethyl-hex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] ester; [(3S,8S,9S,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethyl-hex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; [(3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methyl-hept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] ethanoate; acetic acid [(3S,8S,9S,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethylhex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] ester |
C31H50O2 |
454.73 |
CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)C)C)C)C(C)C |
|
TCMBANKIN012073 |
campest-5-en-3beta-ol |
C01789; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(1R,4R)-1,4,5-trimethylhexyl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5,6-dimethylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; LMST01030097; (24R)ergost-5-en-3beta-ol; CHEBI:28623 |
C28H48O |
400.68 |
CC(C)C(C)CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
|
TCMBANKIN012104 |
14-deoxy-12-methoxyandrographolide |
|
C21H32O5 |
364.5 g/mol |
CC12CCC(C(C1CCC(=C)C2CC(C3=CCOC3=O)OC)(C)CO)O |
|
TCMBANKIN012211 |
4alpha,14alpha,24-trimethylcholesta-8,24-dienol |
4α,14α,24-trimethylcholesta-8,24-dienol |
C30H50O |
426.7 g/mol |
CC1CCCC2(C1CCC3=C2CCC4(C3(CCC4C(C)CCC(=C(C)CO)C)C)C)C |
|
TCMBANKIN012652 |
beta-Cholestanol |
Cholestanol (VAN); 5alpha-Cholestanol; 5alpha-Cholestan-3beta-ol; NSC 18188; ()-Dihydrocholesterol; Dihydrocholesterol; 47129_SUPELCO; Cholestan-3beta-ol; 5alpha-Dihydrocholesterol; 3beta-Hydroxy-5alpha-cholestane; Cholestan-3-ol, (3beta,5alpha)-; 3beta-Hydroxycholestane; EINECS 201-315-8; (3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; 5-alpha-Cholestan-3-beta-ol; 29466-38-4; ZINC04262223; D6128_SIGMA; 118167-50-3; LMST01010077; (3S,5S,8R,9S,10S,13R,14S,17R)-17-[(1R)-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C27H48O |
388.67 |
CC(C)CCCC(C)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C |
|
TCMBANKIN012700 |
coumestrol |
NCIMech_000078; CCRIS 7311; A-Lactone; API0002121; Tox21_200032; MolPort-003-846-031; US8552057, 3; HMS3374A07; 3,9-Dihydroxy-6H-benzofuro[3,2-c]-[1]benzopyran-6-one; 6H-Benzofuro[3,2-c][1]benzopyran-6-one,3,9-dihydroxy-; Cumostrol; CHEBI:3908; C-16836; VZ31590; LS-35394; S00280; 3,9-dihydroxy-[1]benzofuro[3,2-c]chromen-6-one; MFCD00016885; SMP2_000163; DSSTox_RID_76572; 27885_FLUKA; 6H-Benzofuro[3, 3,9-dihydroxy-; 5-19-06-00405 (Beilstein Handbook Reference); BRN 0266702; 479-13-0; NSC22842; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone; C10205; 3,9-dihydroxy-[1]benzoxolo[3,2-c]chromen-6-one; AC1NQYXV; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone (6CI); NCGC00018124-01; DSSTox_CID_2399; CTK8F8799; Coumestrol, >=95.0% (HPLC); NCI60_001863; 4CN-2508; ZZIALNLLNHEQPJ-UHFFFAOYSA-N; BIDD:ER0114; NCGC00018124-03; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one #; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-; A1-00298; NSC 22842; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; CCG-35536; NCGC00018124-06; 3,9-bis(oxidanyl)-[1]benzofuro[3,2-c]chromen-6-one; ZINC1219; NCGC00257586-01; 3,9-Dihydroxy-benzo[4,5]furo[3,2-c]chromen-6-one; AIDS011954; SCHEMBL22012; UNII-V7NW98OB34; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; MLS000069446; CCG-36200; LMPK12090018; 3-Benzofurancarboxylic acid,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 7,12-Dihydroxycoumestan; CS-6343; D02DML; CHEMBL30707; 3,9-dihydroxy-6-benzofurano[3,2-c]chromenone; ZINC00001219; 5,14-dihydroxy-8,17-dioxatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),2,4,6,11(16),12,14-heptaen-9-one; Oprea1_222511; MLS000738006; EINECS 207-525-6; 3,9-Dihydroxycoumestan; Coumestrol, BioReagent, suitable for fluorescence, >=97.5% (HPLC); A827386; DTXSID6022399; CAS-479-13-0; FT-0603177; ST50320052; 2-(2,4-Dihydroxyphenyl)-6-hydroxy-3-benzofurancarboxylic Acid ; 3,9-dihydroxybenzofurano[3,2-c]chromen-6-one; 3,9-dihydroxybenzo[d]chromeno[4,3-b]furan-6-one; NCGC00023462-03; AIDS-011954; V0359; Cumoestrol; DSSTox_GSID_22399; Cumoesterol; NCGC00018124-05; Coumestrol; NCGC00018124-04; V7NW98OB34; ZB000278; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; ST5320052; AN-6463; Cumestrol; NCGC00023462-04; NCGC00018124-02; CC-25990; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihdyroxy-; NSC-22842; 3,9-dihydroxybenzofuro[3,2-c]chromen-6-one; AKOS028111776; HMS2235B05; Coumesterol; COUMESTROL; BDBM23451; SMR000059001; HY-N2335; 27883_FLUKA |
C15H8O5 |
268.22 |
C1=CC2=C(C=C1O)OC3=C2C(=O)OC4=C3C=CC(=C4)O |
|
TCMBANKIN012894 |
TRIPTONOLIDE |
triptonolide; 6-hydroxy-9b-methyl-7-propan-2-yl-3b,4,10,11-tetrahydro-3H-naphtho[2,1-e][2]benzofuran-1,5-dione; AC1NT199 |
C20H22O4 |
326.4 g/mol |
CC(C)C1=C(C2=C(C=C1)C3(CCC4=C(C3CC2=O)COC4=O)C)O |
|
TCMBANKIN013208 |
(6S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-6-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
(6S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethyl-hexyl]-6-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (6S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methyl-heptan-2-yl]-6-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (6S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-6-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
C29H48O2 |
428.69 |
|
|
TCMBANKIN013297 |
przewalskin b |
|
C20H26O4 |
330.4 g/mol |
CC(C)C1=CC23CCC4C(=CCCC4(C)C)C2OC(=O)C3(C1=O)O |
|
TCMBANKIN013564 |
(2S,4aS,10aR)-7-isopropyl-1,1,4a-trimethyl-2,3,4,9,10,10a-hexahydrophenanthren-2-ol |
(2S,4aS,10aR)-1,1,4a-trimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-2-ol |
|
286.5 |
|
|
TCMBANKIN013711 |
Methyl dehydro-15-hydroxy-abietan-18-oate |
methyl dehydro-15-hydroxy-abietan-18-oate |
|
330.51 |
CC12CCCC(C1CCC3=C2C=CC(=C3)C(C)(C)O)(C)C(=O)OC |
|
TCMBANKIN013785 |
beta-cholestane |
LMST01010085; 481-20-9; (5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene; (5S,8R,9S,10S,13R,14S,17R)-17-[(1R)-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene; (5beta)-cholestane; pseudocholestane; 5beta-cholestane; CHEBI:35517 |
C27H48 |
372.67 |
CC(C)CCCC(C)C1CCC2C1(CCC3C2CCC4C3(CCCC4)C)C |
|
TCMBANKIN013951 |
angeloylajadin |
|
|
330.41 |
|
|
TCMBANKIN014016 |
glycoside E_qt |
|
|
334.55 |
|
|
TCMBANKIN014300 |
3β-hydroxystigmast-5-en-7-one |
3β-Hydroxystigmast- 5-en- 7-one |
C29H48O2 |
428.69 |
|
|
TCMBANKIN014474 |
(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene |
(8S,9S,10R,13R,14S,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene |
|
380.72 |
|
|
TCMBANKIN014683 |
Tobacco ene |
|
C9H6Cl6O3S |
|
C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl |
|
TCMBANKIN014754 |
3-[2-[(1R,4aS,5R,8aS)-5,8a-dimethyl-2-methylene-5-methylol-decalin-1-yl]ethyl]-5H-furan-2-one |
3-[2-[(1R,4aS,5R,8aS)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethyl]-5H-furan-2-one; 3-[2-[(1R,4aS,5R,8aS)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-decalinyl]ethyl]-5H-furan-2-one; 3-[2-[(1R,4aS,5R,8aS)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]ethyl]-5H-furan-2-one |
C26H40O8 |
480.59 |
|
|
TCMBANKIN014836 |
(8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene |
(8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene; (8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methyl-heptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene; (8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethyl-hexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene |
C35H60O6 |
576.85 |
|
|
TCMBANKIN014897 |
ZINC03982454 |
(3R,8S,9S,10R,13R,14R,17R)-17-[(2R,5S)-5-ethyl-6-methyl-heptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3R,8S,9S,10R,13R,14R,17R)-17-[(1R,4S)-4-ethyl-1,5-dimethyl-hexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3R,8S,9S,10R,13R,14R,17R)-17-[(1R,4S)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3R,8S,9S,10R,13R,14R,17R)-17-[(2R,5S)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C29H50O |
414.71 |
|
|
TCMBANKIN014922 |
(1R)-1-[(2S,4aR,4bS,7R,8aS)-7-hydroxy-2,4b,8,8-tetramethyl-4,4a,5,6,7,8a,9,10-octahydro-3H-phenanthren-2-yl]ethane-1,2-diol |
1,2-Ethanediol, 1-(2,3,4,4a,4b,5,6,7,8,8a,9,10-dodecahydro-7-hydroxy-2,4b,8,8-tetramethyl-2-phenanthrenyl)-, (2S-(2alpha(S*),4abeta,4balpha,7alpha,8abeta))- |
C20H34O3 |
322.48 |
CC1(C2CCC3=CC(CCC3C2(CCC1O)C)(C)C(CO)O)C |
|
TCMBANKIN015221 |
15alpha-Hydroxy-ent-kaur-16-en-19-oic acid |
CCRIS 1516; NSC 332872 |
C20H30O3 |
318.45 |
CC12CCCC(C1CCC34C2CCC(C3)C(=C)C4O)(C)C(=O)O |
|
TCMBANKIN015237 |
atratoside,a_qt |
|
|
344.49 |
|
|
TCMBANKIN015386 |
β-sitosterol-β-D-glucopyranoside |
|
|
398.79 |
|
|
TCMBANKIN015442 |
ZINC03978781 |
(3S,8R,9R,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethylhex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8R,9R,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethyl-hex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8R,9R,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methyl-hept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8R,9R,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C35H58O6 |
574.83 |
|
|
TCMBANKIN015559 |
24-Dehydrocholesterol |
313-04-2; CHEBI:17737; D6513_SIGMA; Cholesta-5,24-dien-3beta-ol; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 5,24-Cholestadien-3beta-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(1R)-1,5-dimethylhex-4-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; C01802; 3beta-Hydroxy-5,24-cholestadiene; cholest-5,24-dien-3beta-ol; 3beta-cholesta-5,24-dien-3-ol; LMST01010016 |
C27H44O |
384.64 |
CC(CCC=C(C)C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
|
TCMBANKIN015617 |
solanine_qt |
|
C45H73NO15 |
868.06 |
|
|
TCMBANKIN015742 |
pseudoprotodioscin_qt |
|
C51H82O21 |
1031.18 |
|
|
TCMBANKIN015768 |
bisacumol |
|
C15H22O |
218.33 |
CC1=CC=C(C=C1)C(C)CC(C=C(C)C)O |
|
TCMBANKIN016299 |
beta-Sitosterol-beta-D-glucopyranoside_qt |
|
|
398.69 |
|
|
TCMBANKIN016404 |
methyl (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate |
(4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid methyl ester; (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid methyl ester |
C24H40O2 |
360.57 |
|
|
TCMBANKIN016644 |
stigmasterol glucoside_qt |
|
C35H58O6 |
574.83 |
|
|
TCMBANKIN016767 |
salvilenone Ⅰ |
|
270.4 |
32.434709 |
|
|
TCMBANKIN016881 |
beta-sitosterol-beta-d-glucoside_qt |
|
|
416.81 |
|
|
TCMBANKIN016937 |
ergosta-7,22-dien-3β-ol |
24-methylcholesta-7,22-dien-3β-ol; Ergosta-7,22-dien-3β-ol |
|
398.74 |
CC(C)C(=C)CCC(C)C1CCC2C1(CCC3=C2CCC4C3(CCC(C4)O)C)C |
|
TCMBANKIN017129 |
Timosaponin A-1_qt |
|
|
416.71 |
|
|
TCMBANKIN017174 |
androstane-3,11,17-triol |
|
C19H32O3 |
308.5 g/mol |
CC12CCC(CC1CCC3C2C(CC4(C3CCC4O)C)O)O |
|
TCMBANKIN017657 |
4, 7-dimethoxy-5-methylcoumarin |
4,7-dimethoxy-5-methyl-coumarin; 4,7-dimethoxy-5-methyl-2-chromenone; 4,7-dimethoxy-5-methyl-chromen-2-one; 4,7-dimethoxy-5-methylchromen-2-one; 53377-54-1 |
C12H12O4 |
220.22 |
CC1=CC(=CC2=C1C(=CC(=O)O2)OC)OC |
|
TCMBANKIN017755 |
Stigmast-5-en-3beta,24-diol |
(3S,8S,9S,10R,13R,14S,17R)-17-[(1R,4S)-4-ethyl-4-hydroxy-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5S)-5-ethyl-5-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Stigmast-5-ene-3,24-diol, (3beta)-; (3S,8S,9S,10R,13R,14S,17R)-17-[(1R,4S)-4-ethyl-4-hydroxy-1,5-dimethyl-hexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 71208-86-1; (3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5S)-5-ethyl-5-hydroxy-6-methyl-heptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C29H50O2 |
430.71 |
CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)(C(C)C)O |
|
TCMBANKIN017757 |
Oleanolic acid-28-O-beta-D-glucopyranoside |
oleanolicacid-28-o-β-d-glucopyranoside; oleanolic acid-28-o-beta-d-glucopyranoside |
C36H58O8 |
618.8 g/mol |
CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C(=O)OC6C(C(C(C(O6)CO)O)O)O)C |
|
TCMBANKIN017939 |
α-lindane |
|
C6H6Cl6 or ClCH(CHCl)4CHCl |
|
C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl |
|
TCMBANKIN018104 |
leonurinine_qt |
leonuridine_qt |
C15H24O9 |
348.35 |
|
|
TCMBANKIN018158 |
TES |
ZINC03814409; AA 2500; Geno-cristaux Gremy; Testogel; 17beta-Hydroxy-delta(sup4)-androsten-3-one; Testandrone; NSC 9700; Testosterone and its esters; Testoderm; 4-androstene-17beta-ol-3-one; Androgel (TN); Striant (TN); Andrusol; Cristerona T; CCRIS 574; 58-22-0; Perandren; Synandrol F; Androlin; HSDB 3398; BB_NC-0117; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Testim; Orquisteron; Androst-4-en-3-one, 17-beta-hydroxy-; Androst-4-en-3-one, 17-hydroxy-, (17-beta)-; Testopropon; CHEBI:17347; Androst-4-en-3-one, 17-hydroxy, (17.beta.)-; AIDS-070519; COL 1621; delta4-Androsten-17beta-ol-3-one; Halotensin; Testosterone [Androgenic steroids, anabolic]; Virosterone; Teslen; Primotest; delta4-androsten-17b-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one; Testoject-50; Sustason 250; Androst-4-en-3-one, 17-hydroxy-, (17beta)-; CP 601B; Testosteroid; Malogen, aquaspension injection; Testro AQ; Andropatch; Testosterone (JAN/USP); 17b-hydroxy-4-androsten-3-one; Percutacrine androgenique; Oreton; EINECS 200-370-5; Relibra; 17beta-Hydroxyandrost-4-ene-3-one; Testolin; (17beta)-17-Hydroxyandrost-4-en-3-one; Striant; 4-androsten-17beta-ol-3-one; Virilon; 17-Hydroxy-(17-beta)-androst-4-en-3-one; Testosteronum [INN-Latin]; Testosterona [INN-Spanish]; CDB 111C; 46923_RIEDEL; Testostosterone; 17-Hydroxy-(17beta)-androst-4-en-3-one; Testosterone; LibiGel; 9-beta,10-alpha-ANDROST-4-EN-3-ONE, 17-beta-HYDROXY-; Androst-4-en-17beta-ol-3-one; NCGC00091018-01; D00075; delta(sup 4)-Androsten-17(beta)-ol-3-one; T1500_SIGMA; Testim (TN); Mertestate; trans-Testosterone; Testrone; Testosterone [BAN:INN]; S00309; C00535; Malestrone (amps); Testosterone hydrate; Testosterone; 4-Androsten-17?-ol-3-one; 17?-Hydroxy-4-androsten-3-one; Androderm (TN); Testiculosterone; 17beta-Hydroxy-4-androsten-3-one; LMST02020002; Primoteston; Sustanone; Neo-testis; Androst-4-en-3-one, 17beta-hydroxy-; beta testosterone; Testoviron Schering; Andronaq; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; Oreton-F; DEA No. 4000; CMC_13449; Androderm; Cristerone T; c1014; 17beta-Hydroxy-3-oxo-4-androstene; AndroGel; 17beta-Hydroxyandrost-4-en-3-one; Testryl; T5411_SIGMA; Homosteron; Testosteron; Testobase; Andro 100; Virormone; Testosterone solution; Homosterone; Testoviron T; AIDS070519; Malerone |
C19H28O2 |
288.42 |
CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C |
|
TCMBANKIN018346 |
stigmastan-7-one |
|
C29H50O |
414.71 |
CCC(CCC(C)C1CCC2C1(CCC3C2C(=O)CC4C3(CCCC4)C)C)C(C)C |
|
TCMBANKIN018881 |
Triptinin B |
triptinin b |
C20H26O3 |
314.4 g/mol |
CC1=C(CCC2(C1CCC3=C2C=CC(=C3O)C(C)C)C)C(=O)O |
|
TCMBANKIN019426 |
Adlantone |
|
|
412.77 |
|
|
TCMBANKIN019788 |
α-Spinasterol-β-D-glucoside_qt |
|
|
412.77 |
|
|
TCMBANKIN019874 |
(1S,4aS,4bR,7R,10aS)-1,4a,7-trimethyl-7-vinyl-3,4,4b,5,6,9,10,10a-octahydro-2H-phenanthrene-1-carboxylic acid |
(1S,4aS,4bR,7R,10aS)-7-ethenyl-1,4a,7-trimethyl-3,4,4b,5,6,9,10,10a-octahydro-2H-phenanthrene-1-carboxylic acid |
|
302.5 |
|
|
TCMBANKIN020082 |
4a-formyl-7alpha-hydroxy-1-methyl-8-methylidene-4aalpha,4bbeta-gibbane-1alpha,10beta-dicarboxylic acid |
(1S,2S,3S,4R,8R,9R,12S)-8-formyl-12-hydroxy-4-methyl-13-methylidenetetracyclo[10.2.1.0(1,9).0(3,8)]pentadecane-2,4-dicarboxylic acid; GA19; CHEBI:28731 |
C20H26O6 |
362.42 |
CC1(CCCC2(C1C(C34C2CCC(C3)(C(=C)C4)O)C(=O)O)C=O)C(=O)O |
|
TCMBANKIN020392 |
sarsasapogeni |
AKOS025402319; (1'R,2R,2'S,4'R,7'S,8'R,9'S,12'S,13'S)-5,7',9',13'-TETRAMETHYL-5'-OXASPIRO[OXANE-2,6'-PENTACYCLO[10.8.0.0(2),?.0?,?.0(1)(3),(1)?]ICOSAN]-16'-OL; AC-8053; BG01705212; Q-201700 |
C27H44O3 |
416.64 |
CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)O)C)C)C)OC1 |
|
TCMBANKIN020721 |
fernenone |
|
C30H48O |
424.7 g/mol |
CC(C)C1CCC2C1(CCC3(C2(CC=C4C3CCC5C4(CCC(=O)C5(C)C)C)C)C)C |
|
TCMBANKIN021025 |
ergosta-4,24(28)-dien-3-one |
|
C28H44O |
396.6 g/mol |
CC(C)C(=C)CCC(C)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C |
|
TCMBANKIN021503 |
brassicasterol |
Brassicasterol; ergosta-5,22-dienol; ergosta-5,22-dien-3 beta-ol; ergosta-5,22E-dien-3beta-ol; 474-67-9; (3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; C08813; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; LMST01030098 |
C28H46O |
398.66 |
CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
|
TCMBANKIN021806 |
Tetrapanoside B_qt |
|
|
428.77 |
|
|
TCMBANKIN021972 |
darutoside_qt |
|
C26H44O8 |
484.62 |
|
|
TCMBANKIN021990 |
(3S,7S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol |
(3S,7S,8S,9S,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethyl-hex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol; (3S,7S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methyl-hept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol; (3S,7S,8S,9S,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethylhex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol |
|
428.77 |
|
|
TCMBANKIN022158 |
Δ5,22-stigmastadien-3-ol |
|
|
412.77 |
|
|
TCMBANKIN022336 |
3-[2-[(1S,4aR,5S,8aR)-5,8a-dimethyl-2-methylene-5-methylol-decalin-1-yl]ethyl]-5H-furan-2-one |
3-[2-[(1S,4aR,5S,8aR)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-decalinyl]ethyl]-5H-furan-2-one; 3-[2-[(1S,4aR,5S,8aR)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethyl]-5H-furan-2-one; 3-[2-[(1S,4aR,5S,8aR)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]ethyl]-5H-furan-2-one |
|
318.5 |
|
|
TCMBANKIN022364 |
Methyl desoxycholate |
|
C25H42O4 |
406.6 |
CC(CCC(=O)OC)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C |
|
TCMBANKIN022461 |
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R,5S)-5-propan-2-yloctan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
(3S,8S,9S,10R,13R,14S,17R)-17-[(1R,4S)-4-isopropyl-1-methyl-heptyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(1R,4S)-4-isopropyl-1-methylheptyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C30H52O |
428.73 |
|
|
TCMBANKIN022488 |
ergostenol |
|
C28H48O |
400.68 |
CC(CCC(C)C(=CO)C)C1CCC2C1(CCC3C2CCC4C3(CCCC4)C)C |
|
TCMBANKIN022648 |
Timosaponin B III_qt |
|
C45H74O18 |
903.06 |
|
|
TCMBANKIN022689 |
Stigmastan-3,5,22-triene |
|
|
394.75 |
|
|
TCMBANKIN024117 |
14b-pregnane |
|
|
288.57 |
|
|
TCMBANKIN024248 |
(2S,4aR,4bS,7S)-7-isopropyl-1,1,4a-trimethyl-2,4b,5,6,7,8-hexahydrophenanthren-2-ol |
(2S,4aR,4bS,7S)-1,1,4a-trimethyl-7-propan-2-yl-2,4b,5,6,7,8-hexahydrophenanthren-2-ol |
|
286.5 |
|
|
TCMBANKIN024472 |
3β-hydroxy-5α-pregn-16(17)en-20-one-3-O-β-D-xylopyranosyl(1→2)-[β-D-xylopyranosyl-(1→3)]-β-D-glucopyranosyl(1→4)-[α-L-rhamnopyranosyl(1→2)]-β-D-galactopyranoside_qt |
|
|
302.55 |
|
|
TCMBANKIN024777 |
beta-daucosterol_qt |
beta-daucosterol,_qt |
|
414.79 |
|
|
TCMBANKIN024815 |
Spongesterol |
NSC231809; spongesterol; NSC-231809; 17-[(E)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; AC1NSK2O |
C28H48O |
400.7 g/mol |
CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C |
|
TCMBANKIN024859 |
evobioside_qt |
|
C35H54O13 |
682.8 |
|
|
TCMBANKIN024860 |
ZINC04073977 |
(8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methyl-heptan-2-yl]-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethyl-hexyl]-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
C29H48O |
412.69 |
|
|
TCMBANKIN025130 |
Daturametelin A_qt |
|
|
438.66 |
|
|
TCMBANKIN025451 |
(1R,4aR,4bR,10aS)-7-isopropyl-1,4a-dimethyl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid |
(1R,4aR,4bR,10aS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid |
C20H30O2 |
302.45 |
|
|
TCMBANKIN025571 |
CHEBI:20656 |
(5R,8S,9S,10S,13R,14S,17S)-17-ethyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene |
C21H36 |
288.51 |
CCC1CCC2C1(CCC3C2CCC4C3(CCCC4)C)C |
|
TCMBANKIN025795 |
daucosterol_qt |
Daucosterol_qt |
C35H60O6 |
576.85 |
|
|
TCMBANKIN025993 |
l-Verbenone |
1196-01-6; 4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one; ZINC00967601; (1S,5S)-2,7,7-trimethylbicyclo[3.1.1]hept-2-en-4-one; bicyclo[3.1.1]hept-3-en-2-one, 4,6,6-trimethyl-; AI3-23128; (1S,5S)-2,7,7-trimethyl-4-bicyclo[3.1.1]hept-2-enone; Verbenone, (L)-; Pin-2-en-4-one; BB_NC-0220; Bicyclo(3.1.1)hept-3-en-2-one, 4,6,6-trimethyl-, (1S,5S)-; InChI=1/C10H14O/c1-6-4-9(11)8-5-7(6)10(8,2)3/h4,7-8H,5H2,1-3H; NSC 6831; EINECS 214-807-2 |
C10H14O |
150.22 |
CC1=CC(=O)C2CC1C2(C)C |
|
TCMBANKIN026055 |
4alpha-methyl-24-ethylcholesta-7,24-dienol |
17-(5-ethyl-6-methylhept-5-en-2-yl)-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; AC1NSYE4; 4alpha-methyl-24-ethyl cholesta-7,24-dienol; 4α-methyl-24-ethylcholesta-7,24-dienol |
C30H50O |
426.7 g/mol |
CCC(=C(C)CO)CCC(C)C1CCC2C1(CCC3C2=CCC4C3(CCCC4C)C)C |
|
TCMBANKIN026167 |
phytosterol |
|
|
414.79 |
|
|
TCMBANKIN026390 |
[(1R,3R,4R,4aS,8aS)-3,4a,8,8-tetramethyl-6'-oxo-spiro[decalin-4,2'-tetrahydropyran]-1-yl] acetate |
acetic acid [(1R,3R,4R,4aS,8aS)-6'-keto-3,4a,8,8-tetramethyl-spiro[decalin-4,2'-tetrahydropyran]-1-yl] ester; [(1R,3R,4R,4aS,8aS)-3,4a,8,8-tetramethyl-6'-oxospiro[2,3,5,6,7,8a-hexahydro-1H-naphthalene-4,2'-oxane]-1-yl] acetate; [(1R,3R,4R,4aS,8aS)-3,4a,8,8-tetramethyl-6'-oxo-spiro[2,3,5,6,7,8a-hexahydro-1H-naphthalene-4,2'-oxane]-1-yl] ethanoate; acetic acid [(1R,3R,4R,4aS,8aS)-3,4a,8,8-tetramethyl-6'-oxo-1-spiro[decalin-4,2'-tetrahydropyran]yl] ester |
|
336.52 |
|
|
TCMBANKIN026544 |
Danshenol B |
CHEMBL2261307; Phenanthro(1,2-b)furan-11(2H)-one, 1,6,7,8,9,10-hexahydro-10-hydroxy-1,6,6-trimethyl-10-(2-oxopropyl)-, (1R-trans)-; danshenol b; DTXSID80172335; Phenanthro(1,2-b)furan-11(2H)-one, 1,6,7,8,9,10-hexahydro-10-hydroxy-1,6,6-trimethyl-10-(2-oxopropyl)-, (1R,10S)-; AC1MJ0RA; MolPort-039-339-186; ZINC13431690; (1R,10S)-10-hydroxy-1,6,6-trimethyl-10-(2-oxopropyl)-2,7,8,9-tetrahydro-1H-naphtho[8,7-g][1]benzoxol-11-one; (1R,10S)-10-acetonyl-10-hydroxy-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[8,7-g]benzofuran-11-one; (1R,10S)-10-hydroxy-1,6,6-trimethyl-10-(2-oxopropyl)-2,7,8,9-tetrahydro-1H-naphtho[1,2-g][1]benzofuran-11-one; 189308-09-6 |
C22H26O4 |
354.44 |
CC1COC2=C1C(=O)C(C3=C2C=CC4=C3CCCC4(C)C)(CC(=O)C)O |
|
TCMBANKIN027148 |
smilagenin |
EINECS 204-775-8; CHEBI:28933; (25R)-Spirostane-3beta-ol; C08913; 5beta-Spirostan-3beta-ol, (25R)- (8CI); (25R)-Spirostan-3.beta.-ol; Isosarsasapogenin; Spirostan-3-ol, (3.beta.,5.beta.,25R)-; Spirostan-3-ol, (3beta,5beta,25R)- (9CI); NSC93747; NSC 93747; (25R)-5beta-Spirostan-3beta-ol; SMP1_000275; SCHEMBL180193; AI3-44895; Isosarsapogenin; (25R)-Spirostan-3beta-ol; 126-18-1; Smilagenin; 5.beta.-Spirostan-3.beta.-ol, (25R)- |
C27H44O3 |
416.6 g/mol |
CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)O)C)C)C)OC1 |
|
TCMBANKIN027322 |
Scillaren A_qt |
|
C36H52O13 |
692.79 |
|
|
TCMBANKIN027340 |
Delta-D |
(1S)-3-[2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol; Colecalciferol (INN); (1S,3E)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; C05443; (1S,3E)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol; (1S,3E)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexan-1-ol; Delta-D (TN); D00188; Cholecalciferol; (1S)-3-[2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexan-1-ol; Cholecalciferol (JP15/USP); (1S)-3-[2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; Vitamin D3; (1S,3E)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-1-cyclohexanol; ZINC03860822; (5E,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; (5E)-vitamin D_3 / (5E)-cholecalciferol / (5E)-calciol; LMST03020220; (1S)-3-[2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-1-cyclohexanol; 67-97-0 |
C27H44O |
384.64 |
CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C |
|
TCMBANKIN027559 |
p-mentha-1,5-dien-8-ol |
p-Mentha-1, 5-dien-8-ol |
C10H16O |
152.23 g/mol |
CC1=CCC(C=C1)C(C)(C)O |
|
TCMBANKIN027708 |
poriferasterol monoglucoside_qt |
Stigmasterol-3-O-βD-glucopyranoside_qt; stigmasterol-3-O-β-D-glucopyranoside_qt |
C35H58O6 |
574.83 |
|
|
TCMBANKIN027802 |
sendanolactone |
|
C30H42O4 |
466.65 |
CC(=CCCC1C2C(CC3(C2(CCC4C3=CC(=O)C5C4(CCC(=O)C5(C)C)C)C)C)OC1=O)C |
|
TCMBANKIN027872 |
norethynodrel |
|
C20H26O2 |
298.4 g/mol |
CC12CCC3C(C1CCC2(C#C)O)CCC4=C3CCC(=O)C4 |
|
TCMBANKIN027937 |
stigmasta-7-en-3-ol |
|
|
414.79 |
|
|
TCMBANKIN028079 |
ganoderal B |
|
C30H46O3 |
454.68 |
CC(CCC=C(C)C=O)C1CCC2(C1(CCC3=C2C(CC4C3(CCC(=O)C4(C)C)C)O)C)C |
|
TCMBANKIN028092 |
Korseverinine |
korseverinine |
C27H43NO2 |
413.64 |
CC1CCC2C(C3CCC4C(C3CN2C1)CC5=C4CC(C6C5(CCC(C6)O)C)O)C |
|
TCMBANKIN028106 |
(16S, 20R)-dihydroxydammar-24-en-3-one |
|
|
472.83 |
|
|
TCMBANKIN028166 |
tirucallane |
|
C30H54 |
414.7 g/mol |
CC(C)CCCC(C)C1CCC2(C1(CCC3C2CCC4C3(CCCC4(C)C)C)C)C |
|
TCMBANKIN028219 |
TNP00001 |
(1Z,6Z)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; NCGC00017159-01; (1Z,6Z)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione |
C21H20O6 |
368.38 |
COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O |
|
TCMBANKIN028493 |
stigmasterol-3-o-β-d-glucoside_qt |
|
|
398.74 |
|
|
TCMBANKIN028596 |
Isofernene |
AC1NSX0L; (5aS,11aS,13bR)-3a,5a,8,8,11a,13a-hexamethyl-3-propan-2-yl-1,2,3,4,5,6,7,7a,9,10,11,12,13,13b-tetradecahydrocyclopenta[a]chrysene; isofernene |
C30H50 |
410.72 |
CC(C)C1CCC2C1(CCC3(C2(CCC4=C3CCC5C4(CCCC5(C)C)C)C)C)C |
|
TCMBANKIN028904 |
D-Friedoolean-14-en-3-one |
(4aR,6aR,6aS,8aR,12aR,14aR,14bR)-4,4,6a,6a,8a,11,11,14b-octamethyl-2,4a,5,6,8,9,10,12,12a,13,14,14a-dodecahydro-1H-picen-3-one; ZINC04104836 |
C30H48O |
424.7 |
CC1(CCC2(CC=C3C4(CCC5C(C(=O)CCC5(C4CCC3(C2C1)C)C)(C)C)C)C)C |
|
TCMBANKIN029300 |
campesterol-3-O-β-D-glucopyranoside |
|
C34H58O6 |
562.82 |
|
|
TCMBANKIN029678 |
Δ7,16,25,26-stigmastatrienol |
Δ7,22,25-triene-3-β-D-glucoside_qt |
|
410.75 |
|
|
TCMBANKIN029692 |
helichrysoside |
Helichrysoside; LMPK12112144 |
C30H26O14 |
610.52 |
C1=CC(=CC=C1C=CC(=O)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O |
|
TCMBANKIN029969 |
7beta-[3-ethyl-cis-crotonoyloxy]-5,6-dehydro-3,14-dehydro-Z-notonipetralactone |
|
|
370.58 |
|
|
TCMBANKIN029984 |
spirostanol |
|
|
400.71 |
|
|
TCMBANKIN030112 |
Triptonoterpene |
AC1NT19C; triptonoterpene; 8-hydroxy-1,1,4a-trimethyl-7-propan-2-yl-4,9,10,10a-tetrahydro-3H-phenanthren-2-one |
C20H28O2 |
300.4 g/mol |
CC(C)C1=C(C2=C(C=C1)C3(CCC(=O)C(C3CC2)(C)C)C)O |
|
TCMBANKIN030343 |
cucurbita-5,24-dienol |
|
|
440.83 |
|
|
TCMBANKIN030487 |
atratoglaucoside,a_qt |
|
|
360.49 |
|
|
TCMBANKIN030666 |
1,2-epoxyfurano-10(15)-germacren-6-one |
|
|
246.33 |
|
|
TCMBANKIN031036 |
cynanversicoside g_qt 2 |
|
|
344.49 |
|
|
TCMBANKIN031366 |
macrostemonoside e_qt |
|
|
416.71 |
|
|
TCMBANKIN031504 |
ZINC04081584 |
(5S,8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-5,6,7,8,9,11,12,14,15,16-decahydro-4H-cyclopenta[a]phenanthren-3-one |
C20H30O2 |
302.45 |
|
|
TCMBANKIN031627 |
S-trans-N-methyltetrahydrocolumbamine |
|
|
356.48 |
|
|
TCMBANKIN031908 |
Demissine_qt |
|
C50H83NO20 |
1018.19 |
|
|
TCMBANKIN032018 |
isofouquierone |
|
C30H50O3 |
458.72 |
CC1(C2CCC3(C(C2(CCC1=O)C)CCC4C3(CCC4C(C)(CC=CC(C)(C)O)O)C)C)C |
|
TCMBANKIN032043 |
stigmastenol |
|
C29H50O |
414.7 g/mol |
CC(C)C(CCC(C)C1CCC2C1(CCC3C2CCC4C3(CCCC4)C)C)C=CO |
|
TCMBANKIN032159 |
myrrhanones B |
|
|
472.78 |
|
|
TCMBANKIN032316 |
acetic acid [(1R,3R,4R,4aS,8aS)-4-hydroxy-3,4a,8,8-tetramethyl-4-[2-(2-oxo-5H-furan-3-yl)ethyl]-1-decalinyl] ester |
[(1R,3R,4R,4aS,8aS)-4-hydroxy-3,4a,8,8-tetramethyl-4-[2-(2-oxo-5H-furan-3-yl)ethyl]decalin-1-yl] acetate; acetic acid [(1R,3R,4R,4aS,8aS)-4-hydroxy-4-[2-(2-keto-5H-furan-3-yl)ethyl]-3,4a,8,8-tetramethyl-decalin-1-yl] ester; [(1R,3R,4R,4aS,8aS)-4-hydroxy-3,4a,8,8-tetramethyl-4-[2-(2-oxo-5H-furan-3-yl)ethyl]-2,3,5,6,7,8a-hexahydro-1H-naphthalen-1-yl] acetate; [(1R,3R,4R,4aS,8aS)-4-hydroxy-3,4a,8,8-tetramethyl-4-[2-(2-oxo-5H-furan-3-yl)ethyl]-2,3,5,6,7,8a-hexahydro-1H-naphthalen-1-yl] ethanoate |
|
378.56 |
|
|
TCMBANKIN032584 |
(3S,5R,10S,13R,14R,17R)-17-[(1R)-1,5-dimethyl-4-methylenehexyl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol |
(3S,5R,10S,13R,14R,17R)-17-[(1R)-1,5-dimethyl-4-methylene-hexyl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5R,10S,13R,14R,17R)-17-[(1R)-4-isopropyl-1-methyl-pent-4-enyl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methyl-5-methylidene-heptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol |
C31H52O |
440.74 |
|
|
TCMBANKIN032600 |
stigmastan-3,7-diol |
|
|
432.81 |
|
|
TCMBANKIN032662 |
(3S,8S,9S,10R,13R,14S,17R)-17-[(E,1R,4R)-1,4-dimethylhex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(E,2R,5R)-5-methylhept-3-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C29H48O |
412.69 |
|
|
TCMBANKIN032814 |
sphingomyelin |
|
|
493.73 |
CCCCCCCCCCCCCC=CC(C(COP(=O)([O-])OCC[N+](C)(C)C)NC(=O)CCCCCCCCCC=CCCCCCC)O |
|
TCMBANKIN033089 |
butyrospermol |
|
C30H50O |
426.72 |
CC(CCC=C(C)C)C1CCC2(C1(CCC3C2=CCC4C3(CCC(C4(C)C)O)C)C)C |
|
TCMBANKIN033200 |
Lichesterol |
(3S,10S,13R,14R,17R)-10,13-dimethyl-17-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,4,7,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,10S,13R,14R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; C08823; 50657-31-3; Ergosta-5,8,22-trien-3-ol, (3beta,22E)- |
C28H44O |
396.65 |
CC(C)C(C)C=CC(C)C1CCC2C1(CCC3=C2CC=C4C3(CCC(C4)O)C)C |
|
TCMBANKIN033377 |
stigmastadienone |
|
C29H46O |
410.67 |
|
|
TCMBANKIN033516 |
18,19-dihydroxy-5alpha,10beta-neo-cleroda-diene-butenylhydroxyoate |
|
|
334.5 |
|
|
TCMBANKIN033648 |
ergosta-5,7,22-trien-3-ol |
|
C28H44O |
396.6 g/mol |
CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2=CC=C4C3(CCC(C4)O)C)C |
|
TCMBANKIN033723 |
Deoxyandrographolide |
4-[2-[(4aS,5R,6R,8aR)-6-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]ethyl]-2H-furan-5-one; BG01310040; AC-20219; DTXSID60616868; 79233-15-1; ANDROGRAPHOLIDE, DEOXY-; deoxyandrographolide; ZINC21992845; 9342AF; MolPort-005-938-522; AKOS015965180; 3-{2-[(4aS,5R,6R,8aR)-6-Hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-3,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]ethyl}furan-2(5H)-one; 3-{2-[(4AS,5R,6R,8AR)-6-HYDROXY-5-(HYDROXYMETHYL)-2,5,8A-TRIMETHYL-3,4,4A,6,7,8-HEXAHYDRONAPHTHALEN-1-YL]ETHYL}-5H-FURAN-2-ONE; AN-36619; CS-3655; AK546859; HY-N0857; 14-deoxyandrographolide(14-DAP) |
C20H30O4 |
334.45 |
CC1=C(C2(CCC(C(C2CC1)(C)CO)O)C)CCC3=CCOC3=O |
|
TCMBANKIN034087 |
quercetin-3-O-β-D-galactoside |
|
|
464.41 |
|
|
TCMBANKIN034092 |
(3S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-1,4-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R,5R)-5-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
C29H50O |
414.71 |
|
|
TCMBANKIN034112 |
31-norlanosterol |
|
C29H48O |
412.7 g/mol |
CC1C2CCC3=C(C2(CCC1O)C)CCC4(C3(CCC4C(C)CCC=C(C)C)C)C |
|
TCMBANKIN034255 |
Stigmasta-5,22-dien-3-ol-acetate |
|
C31H50O2 |
454.73 |
CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)C)C)C)C(C)C |
|
TCMBANKIN034317 |
(3S,5R,8R,9R,10S,14S)-3,17-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9-hexahydro-1H-cyclopenta[a]phenanthrene-15,16-dione |
(3S,5R,8R,9R,10S,14S)-3,17-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9-hexahydro-1H-cyclopenta[a]phenanthrene-15,16-quinone |
C22H30O4 |
358.47 |
|
|
TCMBANKIN034639 |
Anemarsaponin C_qt |
|
|
416.71 |
|
|
TCMBANKIN035138 |
Senkyunolide-P |
|
C24H30O4 |
382.49 |
CCCCC1C23CCC(C=C2C(=O)O1)C4C3C5=C(CC4)C(=CCCC)OC5=O |
|
TCMBANKIN035256 |
guggulsterol-III |
|
C27H44O3 |
416.6 g/mol |
CC(C)CCCC(C)(C1CCC2C1(CCC3C2CC(C4=CC(=O)CCC34C)O)C)O |
|
TCMBANKIN035306 |
furostanol |
|
C27H46O2 |
402.7 g/mol |
CC1C(OC2C1C3(CCC4C(C3C2)CCC5C4(CCCC5)C)C)CCC(C)CO |
|
TCMBANKIN035449 |
sitgmasterol |
|
|
412.77 |
|
|
TCMBANKIN035624 |
lanost-8-enol |
|
|
428.82 |
|
|
TCMBANKIN035826 |
delta4,16-Androstadien-3-one |
Androsta-4,16-dien-3-one (8CI)(9CI); 4,16-Androstadien-3-one; NSC 93234; (8S,9S,10R,13R,14S)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one |
C19H26O |
270.4 g/mol |
CC12CCC3C(C1CC=C2)CCC4=CC(=O)CCC34C |
|
TCMBANKIN036503 |
alexandrin_qt |
daucosterin_qt |
C35H60O6 |
576.85 |
|
|
TCMBANKIN036640 |
α-amirone |
|
|
422.81 |
|
|
TCMBANKIN036682 |
ZINC01280365 |
(8S,9S,10R,13S,14R,17S)-17-(2-hydroxy-1-oxoethyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (8S,9S,10R,13S,14R,17S)-17-glycoloyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (8S,9S,10R,13S,14R,17S)-17-(2-hydroxyethanoyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; (8S,9S,10R,13S,14R,17S)-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
C21H30O3 |
330.46 |
|
|
TCMBANKIN036721 |
Kanziol |
|
|
440.83 |
|
|
TCMBANKIN036785 |
daucostero_qt |
strumaroside _qt; β-sitosterol-3-O-β-D-glucopyranoside_qt; daucosterol_qt |
C35H60O6 |
576.85 |
|
|
TCMBANKIN036895 |
SAUCHINONE |
SCHEMBL1498622; sauchinone; CHEMBL520054; AKOS030631736; 177931-17-8; ZINC34647724; J-011331; AK683700; Y0181; CTK8G3055; (1S,12R,13S,14R,16R,23R)-13,14-DIMETHYL-2,6,8,20,22-PENTAOXAHEXACYCLO[10.10.1.0(1),(1)?.0(3),(1)(1).0?,?.0(1)?,(2)(3)]TRICOSA-3,5(9),10,18-TETRAEN-17-ONE; MolPort-027-720-909 |
C20H20O6 |
356.37 |
CC1CC2C3C(C1C)C4=CC5=C(C=C4OC36C(=CC2=O)OCO6)OCO5 |
|
TCMBANKIN037067 |
β-Cedrene |
beta-cedrene; DYLPEFGBWGEFBB-OSFYFWSMSA-N; CTK8F1427; A-Cedrene; (+)-; (+)-?-CEDRENE; 6QL7ERD5Q1; 1H-3a,7-Methanoazulene, octahydro-3,8,8-trimethyl-6-methylene-, (3R,3aS,7S,8aS)-; AKOS015896901; 546-28-1; KB-62482; (+)-beta-Funebrene; (+)-beta-Cedrene, >=95.0% (sum of enantiomers, GC); 1H-3a,7-Methanoazulene, octahydro-3,8,8-trimethyl-6-methylene-, [3R-(3.alpha.,3a.beta.,7.beta.,8a.alpha.)]-; UNII-6QL7ERD5Q1; (3R-(3alpha,3Abeta,7beta,8aalpha))-octahydro-3,8,8-trimethyl-6-methylene-1H-3a,7-methanoazulene; 1H-3a,7-Methanoazulene,octahydro-3,8,8-trimethyl-6-methylene-,(3R,3aS,7S,8aS)-; (+)-beta-Cedrene; ZINC59778864; (+)-.beta.-Cedrene; (3R,3aS,7S,8aS)-3,8,8-Trimethyl-6-methyleneoctahydro-1H-3a,7-methanoazulene; .beta.-Cedrene; EINECS 208-898-8; (1S,2R,5S)-8-Methylene-2,6,6-trimethyltricyclo[5.3.1.01.5]undecane; 1H-3a,7-Methanoazulene, octahydro-3,8,8-trimethyl-6-methylene-, (3R-(3alpha,3abeta,7beta,8aalpha))-; beta-Cedrene |
|
204.35 |
|
|
TCMBANKIN037685 |
Lucialdehyde B |
480439-84-7; CHEBI:66593; ZINC38562918; CHEMBL463372; lucialdehyde b; (24E)-3,7-dioxolanosta-8,24-dien-26-al; lucialdehyde B |
C30H44O3 |
453 |
C1([H])([H])C([H])([H])[C@](C([H])([H])[H])(C(C([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])([C@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])\C([H])=C(\C([H])=O)/C([H])([H])[H])C([H])([H])C2([H]
)[H])[C@@]23C([H])([H])[H])=C3C(=O)C4([H])[H])[C@@]4([H])C(C([H])([H])[H])(C([H])([H])[H])C1=O |
|
TCMBANKIN037739 |
Helioscopinolide A |
helioscopinolide a |
|
316.4 g/mol |
|
|
TCMBANKIN037811 |
15α-hydroxymansumbinone |
|
|
328.59 |
CC1(C2CCC3(C(C2(CCC1=O)C)CCC4C3(C(C=C4)O)C)C)C |
|
TCMBANKIN038167 |
24alpha-ethyl-5alpha-cholestan-3beta-ol |
24α-ethyl-5α-cholestan-3β-ol |
C29H52O |
416.72 |
C1([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])(C([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])([C@@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])(C([
H])([H])[H])C([H])([H])[H])C([H])([H])C2([H])[H])[C@]23[H])[C@@]3([H])C([H])([H])C4([H])[H])[C@]4([H])C([H])([H])[C@@]1([H])O[H] |
|
TCMBANKIN038293 |
progesterone |
Cyclogesterin; Luteovis; Progeffik; (8S,9S,10R,13S,14S,17S)-17-ethanoyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Gesterol 50; Corlutin; Syngestrets; NCGC00090798-02; D4-Pregnene-3,20-dione; Hormoluton; Pranone; Crinone progesterone gel; Gesterol 100; Prometrium; Proluton; Luteodyn; Prestwick0_000477; Progestasert; SPBio_002553; .delta.4-Pregnene-3,20-dione; Pregnenedione; NSC-9704; P3972_SIGMA; Methylpregnone; 4-Pregnene-3,20-dione; Prolutone; U 3672; Lutocylin; Colprosterone; Utrogest; Lutocylol; CHEBI:17026; SMR000058345; Corporin; Lipolutin; NCGC00090798-01; P8783_SIGMA; Synovex S; ACon1_002078; 3,20-Pregnene-4; Prestwick_411; Progesterone, water-soluble; Cyclogest; progesterone ; Luteal hormone; Prolets; AIDS070516; NCI60_042166; (S)-Pregn-4-en-3,20-dione; 6.alpha.-Methylpregn-4-en-17.alpha.-ol-3,20-dione; Prolidon; NSC 64377; (8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Nalutron; Progesterone [BAN:INN:JAN]; Progesteronum [INN-Latin]; STR; Flavolutan; Percutacrine Luteinique; Prontogest; Lutocyclin M; Akrolutin; Lugesteron; Corlutina; SCHEMBL12237373; ZINC03814383; Gynlutin; Gynoluton; Prestwick3_000477; Lutogyl; Progesterone: 2-hydroxypropyl-beta-cyclodextrin complex; Crinone (TN); Gynolutone; Spectrum5_002053; Gesterol; AIDS-070516; Progestronol; Luteopur; Corpus luteum hormone; Lutoform; Luteol; 6alpha-Methylpregn-4-en-17alpha-ol-3,20-dione; 17alpha-Progesterone; STOCK1N-52522; Progesterona [INN-Spanish]; Hormoflaveine; Pregn-4-ene-3,20-dione, 17alpha-hydroxy-6alpha-methyl-; Progesterone [Progestins]; Delta(4)-pregnene-3,20-dione; Progesterone: HBC complex; Delta4-Pregnene-3,20-dione; .beta.-Progesterone; Piaponon; Progestrel; Primolut; Gestone; Pregnene-3,20-dione; Syntolutan; NSC64377; MEGxm0_000472; Progesteron; Gelbkoerperhormon; Membrettes; Progestogel; Gestron; EU-0100895; MLS000028517; Prolutin; EINECS 200-350-6; Luteinique; 57-83-0; Progestron; P9776_SIGMA; NCGC00179853-01; Luteol (VAN); Utrogestan; Lutidon; Progesterol; Luteosan; Gestormone; Gestiron; Progesterone; Lutocuclin M; D00066; Endometrin; Lutin; Progestol; Fologenon; C00410; BG01605063; Lucorteum; 8023-13-0; AI3-51682; 8012-32-6; Luteogan; Agolutin; Progesterone (JP15/USP/INN); 17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; MLS000758277; Crinone; 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; Luteohormone; S00293; BPBio1_000676; 17.alpha.-Progesterone; Pregn-4-ene-3,20-dione, 17.alpha.-hydroxy-6.alpha.-methyl-; CMC_13406; NSC 9704; NCGC00022185-06; Luteocrin normale; Progestosol; Protormone; (S)-4-Pregnene-3,20-dione; P6149_SIGMA; Luteine; Lutren; P7556_ALDRICH; 257630-50-5; COL-1620; MolPort-001-740-063; SBB012538; delta(sup4)-Pregnene-3,20-dione; NSC9704; component of Cyclogesterin; Syngesterone; FE-999913; Bio-luton; Prestwick1_000477; NCGC00022185-07; nchembio.2007.53-comp14; Pregn-4-ene-3,20-dione; (1S,3BS,9AR,11AS)-1-ACETYL-9A,11A-DIMETHYL-1H,2H,3H,3AH,3BH,4H,5H,8H,9H,9BH,10H,11H-CYCLOPENTA[A]PHENANTHREN-7-ONE; 753497-20-0; CCRIS 533; Vitarrine; delta(sup 4)-Pregnene-3,20-dione; Progestone; Luteum; Lipo-Lutin; Progestin; Lutociclina; Progesteronum; WLN: L E5 B666 OV MUTJ A1 E1 FV1; Progekan; .delta.(sup4)-Pregnene-3,20-dione; 46665_RIEDEL; AKOS030503393; Projestaject; Lingusorbs; Lucorteum Sol; Lopac0_000895; Lutex; P0130_SIGMA; Prochieve; Corluvite; BSPBio_000614; BRD-A51738545-001-01-0; Prestwick2_000477; Luteostab; Progesterone; 4-Pregnene-3,20-dione; Lutocyclin; Glanducorpin; Prometrium (TN); HSDB 3389; Lutromone; (S)-Progesterone |
C21H30O2 |
314.46 |
CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C |
|
TCMBANKIN038555 |
Triptonoterpene methyl ether |
AC1NT19F; triptonoterpene methyl ether; 5-hydroxy-8-methoxy-1,1,4a-trimethyl-7-propan-2-yl-4,9,10,10a-tetrahydro-3H-phenanthren-2-one |
C21H30O3 |
330.5 g/mol |
CC(C)C1=CC(=C2C(=C1OC)CCC3C2(CCC(=O)C3(C)C)C)O |
|
TCMBANKIN038707 |
alpha-amyrin |
α-Amyrin; C08615; Urs-12-en-3-ol; Urs-12-en-3-ol, (3beta)- (9CI); alpha-Amyrine; Urs-12-en-3.beta.-ol; ST5411384; (3S,4aR,6aR,6bS,8aR,11R,12S,12aR,14aR,14bR)-4,4,6a,6b,8a,11,12,14b-octamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1H-picen-3-ol; (3S,4aR,6aR,6bS,8aR,11R,12S,12aR,14aR,14bR)-4,4,6a,6b,8a,11,12,14b-Octamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-eicosahydro-picen-3-ol; (3.beta.)-Urs-12-en-3-ol; 3-epi-α-amyrin; A834570; Urs-12-en-3-ol #; FSLPMRQHCOLESF-UHFFFAOYSA-N; EINECS 211-352-1; MCULE-7089035597; 12-ursen-3beta-ol; .alpha.-Amyrine; α-amyrin; NSC-114787; alpha-Amyrin; AC1L5E7U; Urs-12-en-3beta-ol; alpha-Amyrenol; Viminalol; 638-95-9; AIDS-070313; Epi-alpha-amyrin; 53017_FLUKA; AIDS070313; AC1Q7B25; .alpha.-Amyrin; 4,4,6a,6b,8a,11,12,14b-octamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1H-picen-3-ol; NSC 114787; NSC114787; alpha-amyrin ; Urs-12-en-3-ol, (3.beta.)-; .alpha.-Amyrenol; LMPR01060011; α- amyrin; SMP2_000308 |
C30H50O |
426.72 |
CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1C)C)C |
|
TCMBANKIN039128 |
Isofucosterol |
C08812; (3S,8S,9S,10R,13R,14S,17R)-17-[(Z,1R)-4-isopropyl-1-methylhex-4-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; C08821; AIDS113090; 481-14-1; isofucosterol; (3S,8S,9S,10R,13R,14S,17R)-17-[(Z,1R)-4-isopropyl-1-methyl-hex-4-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; AIDS-113090; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(Z,2R)-5-propan-2-ylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 18472-36-1; delta5-Avenasterol |
C29H48O |
412.69 |
CC=C(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN039211 |
Haginin E |
|
|
240.25 g/mol |
|
|
TCMBANKIN039516 |
(22E,24R)-ergosta-7,22-dien-3-one |
|
C28H44O |
397 |
C1([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])(C([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])([C@]([H])(C([H])([H])[H])\C([H])=C([H])\[C@]([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H
])([H])[H])C([H])([H])C2([H])[H])[C@]23[H])C3=C([H])C4([H])[H])[C@@]4([H])C([H])([H])C1=O |
|
TCMBANKIN039707 |
GA121-isolactone |
|
|
330.41 |
|
|
TCMBANKIN040689 |
ent-Kaur-15-en-17-ol |
Kaur-15-en-17-ol; Ent-kaur-15-en-17-ol; 14696-33-4 |
|
288.47 |
|
|
TCMBANKIN042009 |
Abridin |
|
|
368.55 |
|
|
TCMBANKIN042116 |
7-Dehydrosigmasterol |
7-dehydrosigmasterol |
C29H50O |
414.79 |
[C@]1([H])(O[H])C([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])(C([H])([H])C([H])([H])[C@@]([C@@]([H])([C@]([H])(C([H])([H])C([H])([H])[C@]([H])(C([H])([H])C([H])([H])[H])C([H])(C([H])([H])[H])C
([H])([H])[H])C([H])([H])[H])C([H])([H])C2([H])[H])(C([H])([H])[H])[C@@]23[H])C3=C([H])C4([H])[H])[C@]4([H])C1([H])[H] |
|
TCMBANKIN042151 |
ergosterol peroxide |
ergosterol peroxide; 2061-64-5; ergosterolperoxide; dimethyl-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl][?]ol; (3.beta.,5.alpha.,8.alpha.,22E)-5,8-Epidioxyergosta-6,22-dien-3-ol |
C56H86O2 |
791 |
O([C@]1([H])C([H])([H])C([C@@](C([H])([H])[H])([C@]([H])(C([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])([C@]([H])(C([H])([H])[H])\C([H])=C([H])\[C@@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])C
([H])([H])[H])C([H])([H])C2([H])[H])[C@]23[H])C3=C4[H])C([H])([H])C1([H])[H])=C4[H])O[C@]5([H])C([H])([H])C([C@@](C([H])([H])[H])([C@]([H])(C([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])([C@]([
H])(C([H])([H])[H])\C([H])=C([H])\[C@@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H])C([H])([H])C6([H])[H])[C@]67[H])C7=C8[H])C([H])([H])C5([H])[H])=C8[H] |
|
TCMBANKIN042397 |
Dammara-20,24-dien-3beta-ol |
dammara-20,24-dien-3β-ol; dammara-20,24-dien-3beta-ol |
C30H50O |
468.75 |
[C@@]1([H])(O[H])C([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])(C([H])([H])C([H])([H])[C@]([H])([C@]([H])(C(C([H])([H])C([H])([H])\C([H])=C(/C([H])([H])[H])\C([H])([H])[H])=C([H])[H])C([H])([H]
)C2([H])[H])[C@@]23C([H])([H])[H])[C@@]3(C([H])([H])[H])C([H])([H])C4([H])[H])[C@]4([H])C1(C([H])([H])[H])C([H])([H])[H] |
|
TCMBANKIN044018 |
Previtexilactone |
previtexilactone |
|
379 |
|
|
TCMBANKIN044549 |
Vitetrifolin E |
|
|
365 |
|
|
TCMBANKIN045792 |
Obtusifoliol |
(3S,4S,5S,10S,13R,14R,17R)-4,10,13,14-tetramethyl-17-[(2R)-6-methyl-5-methylidene-heptan-2-yl]-1,2,3,4,5,6,7,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol; 16910-32-0; 4alpha,14alpha-Dimethyl-5alpha-ergosta-8,24(28)-dien-3beta-ol; obtusifoliol; (3S,4S,5S,10S,13R,14R,17R)-17-[(1R)-4-isopropyl-1-methyl-pent-4-enyl]-4,10,13,14-tetramethyl-1,2,3,4,5,6,7,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol; Ergosta-8,24(28)-dien-3-ol, 4,14-dimethyl-, (3beta,4alpha,5alpha)-; (3S,4S,5S,10S,13R,14R,17R)-17-[(1R)-1,5-dimethyl-4-methylene-hexyl]-4,10,13,14-tetramethyl-1,2,3,4,5,6,7,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol; 4alpha,14alpha-Dimethyl-24-methylene-5alpha-cholesta-8-en-3beta-ol; LMST01030101; 4alpha,14alpha-dimethyl-24-methylene-cholest-8-en-3beta-ol; (3S,4S,5S,10S,13R,14R,17R)-17-[(1R)-1,5-dimethyl-4-methylenehexyl]-4,10,13,14-tetramethyl-1,2,3,4,5,6,7,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol; (3S,4S,5S,10S,13R,14R,17R)-4,10,13,14-tetramethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-1,2,3,4,5,6,7,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol; C01943; 22332-15-6 |
|
426.72 |
|
|
TCMBANKIN045865 |
12s,16s(r)-dihydroxy-ent-labda-7,13-dien-15,16-olide |
|
|
334.5 |
|
|
TCMBANKIN046272 |
14-Deoxy-11,12-didehydroandrographolide |
MLS001143514; CHEMBL1326087; 4-[(E)-2-[(1R,5R,6R,8aR)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]vinyl]-2H-furan-5-one; SMR001215698; 3-[(E)-2-[2-Methylene-5,8aalpha-dimethyl-5alpha-(hydroxymethyl)-6alpha-hydroxydecalin-1alpha-yl]vinyl]furan-2(5H)-one; 14-deoxy-11,12-didehydroandrographolide; SCHEMBL13583643; HMS2270M24 |
C20H28O4 |
332.43 |
CC12CCC(C(C1CCC(=C)C2C=CC3=CCOC3=O)(C)CO)O |
|
TCMBANKIN046339 |
14alpha-Methyl-5alpha-ergosta-9(11)-en-3beta-ol |
14alpha-methyl-5alpha-ergosta-9(11)-en-3beta-ol; 14α-methyl-5α-ergosta-9(11)-en-3β-ol |
C29H50O |
414.7 g/mol |
CC(C)C(C)CCC(C)C1CCC2(C1(CC=C3C2CCC4C3(CCC(C4)O)C)C)C |
|
TCMBANKIN047384 |
diayangambin |
CTK4E6827; DTXSID10175733; SCHEMBL17385618; AC1L4ZYE; (1r,3ar,4r,6ar)-1,4-bis(3,4,5-trimethoxyphenyl)tetrahydro-1h,3h-furo[3,4-c]furan; 1H,3H-Furo(3,4-c)furan, tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-,(1R,3aR,4R,6aR)-; Diayangambin; (+)-Diayangambin; AC1Q70YI; (3R,3aR,6R,6aR)-3,6-bis(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan; Tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-(1R)-1alpha,3abeta,4alpha,6abeta-1H,3H-furo(3,4-c)furan; 21453-68-9; ZINC31477287 |
C24H30O8 |
446.49 |
COC1=CC(=CC(=C1OC)OC)C2C3COC(C3CO2)C4=CC(=C(C(=C4)OC)OC)OC |
|
TCMBANKIN047394 |
isoglaucanone |
|
C27H44O |
385 |
C1([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])(C([H])([H])C([H])([H])[C@]([H])([C@@](C([H])([H])[H])(C([H])([H])C([H])([H])C2=O)[C@]2([H])C([H])([H])C3([H])[H])[C@@]34C([H])([H])[H])[C@@]4(C([
H])([H])[H])C([H])([H])C5([H])[H])[C@]5([H])C(C([H])([H])[H])(C([H])([H])[H])C1([H])[H] |
|
TCMBANKIN047772 |
isopropylidenkirenol |
|
C23H38O4 |
379 |
[C@@]1([H])(O[H])C([H])([H])[C@@](C([H])([H])[H])([C@@]2([H])C(=C([H])[C@@](C([H])([H])[H])([C@@]3([H])OC(C([H])([H])[H])(C([H])([H])[H])OC3([H])[H])C([H])([H])C2([H])[H])C([H])([H])C4([H])[H])[C@@]4(
[H])[C@@](C([H])([H])O[H])(C([H])([H])[H])C1([H])[H] |
|
TCMBANKIN047925 |
Helioscopinolide C |
helioscopinolide c |
|
330.42 |
|
|
TCMBANKIN047970 |
14-deoxyandrographolide |
14-deoxyandrographolide-19-β-D-glucoside_qt; 14-deoxy-andrographolide |
C20H30O4 |
334.45 |
C1([H])([H])C([H])([H])[C@@](C([H])([H])[H])([C@]([H])(C([H])([H])C([H])([H])C2=C([H])C([H])([H])OC2=O)C(=C([H])[H])C([H])([H])C3([H])[H])[C@@]3([H])[C@](C([H])([H])[H])(C([H])([H])O[H])[C@]1([H])O[H] |
|
TCMBANKIN048290 |
Siegesesteric acid II |
siegesesteric acid ii |
C22H36O3 |
348.58 |
C1([H])([H])C([H])([H])[C@@](C([H])([H])[H])([C@]2([H])[C@]3(C([H])([H])[C@]([H])([C@@](C([H])([H])OC([H])([H])C([H])([H])[H])([H])C3([H])[H])C([H])([H])C2([H])[H])C([H])([H])C4([H])[H])[C@@]4([H])[C@
](C([H])([H])[H])(C(O[H])=O)C1([H])[H] |
|
TCMBANKIN048310 |
beta-sitosterol 3-O-glucoside |
|
C35H60O6 |
576.85 |
|
|
TCMBANKIN048379 |
GA122-isolactone |
|
|
330.41 |
|
|
TCMBANKIN048450 |
xysmalogenin |
|
C23H32O4 |
372.5 |
CC12CCC(CC1=CCC3C2CCC4(C3(CCC4C5=CC(=O)OC5)O)C)O |
|
TCMBANKIN049484 |
phyllocladene |
|
C20H32 |
272.47 |
CC1(CCCC2(C1CCC34C2CCC(C3)C(=C)C4)C)C |
|
TCMBANKIN049540 |
Helioscopinolide B |
helioscopinolide b |
|
316.43 |
|
|
TCMBANKIN049945 |
Picropolygamain |
|
|
352.34 |
|
|
TCMBANKIN058060 |
gallic acid |
Spectrum4_001544; NSC-755825; 4CN-0954; KBio2_000822; NCGC00260064-01; KBio3_001168; CHEBI:30778; GTPL5549; D0Y3TZ; NCGC00091125-01; 632XD903SP; ARONIS23903; Spectrum5_000108; Jsp002851; T7419; Gallic acid, puriss., 98.0%; I14-9302; NCGC00091125-07; ZINC1504; 3,4,5-trihydroxybenzoic acid (ACD/Name 4.0); KBioGR_002008; AK-65266; pyrogallol-5-carboxylate; BRD-K77345217-001-01-9; Gallicum acidum; LNTHITQWFMADLM-UHFFFAOYSA-N; KBio2_003390; EBD679760; NCGC00091125-04; AJ-08037; Gallic acid; ZB000350; BG01502846; A808977; (?)-Gallic acid; WLN: QVR CQ DQ EQ; N1830; AC1NEVA5; SBB008781; 149-91-7; GALLIC ACID ANHYDROUS; Gallic acid [NF]; KS-00000IWM; CS-8191; LS-870; C01424; KS-00004784; CHEBI:16918; SPECTRUM210369; c0006; UNII-632XD903SP; ACMC-20aku5; CTK0H5618; BIDD:ER0374; AC1Q732X; NCGC00091125-02; F1908-0156; Oprea1_087792; CG0029; DSSTox_RID_75711; Kyselina 3,4,5-trihydroxybenzoova; 3-10-00-02070 (Beilstein Handbook Reference); RP23206; NSC36997; Gallic acid, certified reference material, TraceCERT(R); AI3-16412; CCG-38670; STK298718; Tox21_202515; bmse000389; AN-15162; AB00052697_03; SR-05000001537-2; NSC-36997; 1886-EP2374526A1; 5-Carboxybenzene-1,2,3-triol; KBio2_005958; SR-05000001537-3; NCGC00091125-05; KBio1_001347; Kyselina gallova [Czech]; KSC175M1R; KBioSS_000822; HMS2091A07; gallate; CPD-183; Spectrum3_000254; 78563C7D-0E2D-4766-A8EA-670A03C78FCF; gallic acid ; InChI=1/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12; GDE; SBI-0052184.P002; EINECS 205-749-9; CAS-149-91-7; Kyselina gallova; J3.617.291F; Benzoic acid, 3,4,5-trihydroxy-; BG00601456; DivK1c_006403; Benzoic acid,4,5-trihydroxy-; gallic acid for microelectronic industrial; BRN 2050274; Gallic acid tech.; NCGC00091125-03; Kyselina 3,4,5-trihydroxybenzoova [Czech]; Gallic acid, 97.5-102.5% (titration); gallicacid; 3,4,5-Trihydroxybenzoic acid, anhydrous; NSC674319; TR-020762; 3,4,5-tris(oxidanyl)benzoate; MCULE-1552954312; Gallic acid polymer; Pharmakon1600-00210369; BSPBio_001668; Tox21_111089; HMS1923K07; CCRIS 5523; BDBM50085536; NSC-674319; ST2404570; BB_SC-2795; AC-1206; 3,4,5-trihydroxy-Benzoic acid; Gallic Acid Hydrate; AC1L1934; RTR-020762; GALOP; Q-201146; SR-05000001537-1; DSSTox_CID_650; 3,4,5-Trihydroxybenzoic acid monohydrate, ACS, 98.0% min. 100g; 3,4,5-Trihydroxybenzoic acid ion; GALLICACID; s4603; CHEMBL288114; Gallic acid, tech.; NSC20103; 3,4,5-Trihydroxybenzoic acid; NSC755825; G0011; AB1002218; Gallic Acid, F; MolPort-000-881-260; NSC 674319; SPBio_000617; LNTHITQWFMADLM-UHFFFAOYSA-M; Spectrum_000342; PS-8710; SC-46383; FT-0626592; BBL009937; MFCD00002510; SpecPlus_000307; 3,4,5-trihydroxy-Benzoate; SCHEMBL15012; DSSTox_GSID_20650; ST083487; SR-05000001537; 3,5-Trihydroxybenzoic acid; 3,4,5-Trihydroxybenzoate, X; Tox21_111089_1; Gallic acid (Monohydrate or Anhydrous) (3,4,5-Trih; 3,4,5-Trihydroxybenzoic acid;; Z966690556; 3,4,5-Trihydroxybenzoate; SDCCGMLS-0066503.P001; Pyrogallol-5-carboxylic acid; BC200279; Spectrum2_000399; HY-N0523; HSDB 2117; AC1Q732Y; DTXSID0020650; 5-Trihydroxybenzoic acid; AKOS000119625; NSC 20103; Gallic acid, tech; 138-57-8; NSC-20103; AIDS-001349; gallate; CPD-183; Spectrum3_000254; KBio2_000822; Gallic acid monohydrate; AIDS-059239; KBio3_001168; Gallic acid, tech.; NSC20103; 3,4,5-Trihydroxybenzoic acid; InChI=1/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12; C01424; CHEBI:30778; EINECS 205-749-9; CHEBI:16918; NCGC00091125-01; c0006; J3.617.291F; SPECTRUM210369; Benzoic acid, 3,4,5-trihydroxy-; DivK1c_006403; NSC 674319; SPBio_000617; LNTHITQWFMADLM-UHFFFAOYSA-M; Spectrum_000342; Spectrum5_000108; NCGC00091125-02; BRN 2050274; Oprea1_087792; NCGC00091125-03; 3-10-00-02070 (Beilstein Handbook Reference); SpecPlus_000307; Kyselina 3,4,5-trihydroxybenzoova [Czech]; KBioGR_002008; AI3-16412; NSC674319; pyrogallol-5-carboxylate; 3,4,5-tris(oxidanyl)benzoate; AIDS001349; KBio2_003390; Gallic acid polymer; 1886-EP2374526A1; ZB000350; Gallic acid; BSPBio_001668; KBio2_005958; AIDS059239; CCRIS 5523; 3,4,5-Trihydroxybenzoate; SDCCGMLS-0066503.P001; Pyrogallol-5-carboxylic acid; A808977; 27645_RIEDEL; KBio1_001347; 398225_SIAL; Kyselina gallova [Czech]; WLN: QVR CQ DQ EQ; Spectrum2_000399; HSDB 2117; G7384_SIGMA; KBioSS_000822; GALOP; AC1NEVA5; SBB008781; 3,4,5-Trihydroxybenzoic acid monohydrate, ACS, 98.0% min. 100g; NSC 20103; 3,4,5-Trihydroxybenzoic acid ion; 149-91-7; 3,4,5-trihydroxybenzoic acid; Galllic acid |
C7H6O5 |
170.12 |
C1=C(C=C(C(=C1O)O)O)C(=O)O |
|
TCMBANKIN058159 |
Rosmarinate |
537-15-5; InChI=1/C18H16O8/c19-12-4-1-10(7-14(12)21)3-6-17(23)26-16(18(24)25)9-11-2-5-13(20)15(22)8-11/h1-8,16,19-22H,9H2,(H,24,25)/b6-3; (2S)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)acryloyl]oxy-propionic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxypropanoic acid; C01850; 3-(3,4-Dihydroxy-phenyl)-acrylic acid 1-carboxy-2-(3,4-dihydroxy-phenyl)-ethyl ester; benzenepropanoic acid, alpha-[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-3,4-dihydroxy-; (2S)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)-1-oxoprop-2-enoxy]propanoic acid; 3-(3,4-dihydroxyphenyl)-2-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}propanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; CHEBI:17226;Rosemary acid;labiatenicacid;rosmarinic acid;rosmarinic |
C18H16O8 |
360.31 |
C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O |
|
TCMBANKIN058205 |
trans-resveratrol |
(E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene |
C14H12O3 |
228.24 g/mol |
C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
|
TCMBANKIN058213 |
kaemferol;kampferol;kaempferol;campherol |
TNP00039; nchembio.2007.28-comp30; Kaempherol; 5-18-05-00251 (Beilstein Handbook Reference); Prestwick2_001098; CHEBI:28499; Prestwick1_001098; CAS-520-18-3; BRN 0304401; Flavone, 3,4',5,7-tetrahydroxy-; ST030560; MEGxp0_001283; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; C.I. 75640; Swartziol; K0133_SIGMA; kaempferol oxoanion; NCGC00016480-01; 60010_FLUKA; EINECS 208-287-6; Pelargidenon; Nimbecetin; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NSC 407289; 3,4',5,7-Tetrahydroxyflavone; HSCI1_000027; Pelargidenolon 1497; NSC407289; Robigenin; C05903; CPD1F-90; Kampferol; NSC 656277; Prestwick0_001098; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; Populnetin; Kampcetin; Prestwick3_001098; AIDS-001404; ZINC00137345; kaempferol ; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-olate; 3,4′,5,7-Tetrahydroxyflavone; Rhamnolutein; NCGC00016480-02; ACon1_001867; NSC656277; 3,4′,5,7-Tetrahydroxyflavone; BSPBio_001176; SPBio_003058; Oprea1_650954; 5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI); Campherol; 520-18-3; 3,5,7-TRIHYDROXY-2-(4-HYDROXYPHENYL)-4H-CHROMEN-4-ONE; S00111; Trifolitin; Kampherol; AI3-36096; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromone; Indigo yellow; Pelargidenolon; AIDS001404; nchembio718-comp14; NCGC00091036-01; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); CHEBI:58573; Kaemferol; Kempferol; BPBio1_001294; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Rhamnolutin; 3,5,7-triOH-Flavone; KMP; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- |
C15H10O6 |
286.24 g/mol |
C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O |
|
TCMBANKIN058215 |
kaempferol-3-o-beta-d-glucoside |
kaempferol-3-O-β-D-glucopyranoside;Kaempferol-3-glucoside;astragalin;Kaempferol-3-o- glucoside;kaempferol 3-glucoside;Kaempferol 3-O-glucoside;kaempferol-3-o-glucoside;5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl beta-D-glucopyranoside; Kaempferol-3-O-.beta.-D-glucopyranoside; Kaempferol-3-beta-glucopyranoside; 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; NCGC00163580-01; 4H-1-Benzopyran-4-one, 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-; Astragaline; 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-chromen-4-one; Kaempferol-3-D-glucoside; 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; MEGxp0_000168; Kaempferol-3-beta-monoglucoside; Kaempferol-3-O-glucoside; 3,4',5,7-Tetrahydroxyflavone-3-glucoside; 480-10-4; ACon1_001224; SCHEMBL23898; 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-chromone; AIDS-051935; AIDS051935; CHEBI:30200; LMPK12111725; Kaempferol 3-O-beta-D-glucopyranoside; C12249; Astragalin; Kaempferol 3-O-glucoside; Kaempferol 3-glucoside; 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; Kaempferol 3-O-beta-D-glucoside; 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]-4-chromenone;kaempferol-3-β-D-glucopyranoside;Kaempferol-3-O-β-D- glucopyranoside; kaempferol-3-o-beta-d-glucopyranoside;kaempferol-3-O-β-D-glucoside; Kaempferol-3-o-β-D- glucoside; Kaempferol- 3-O-β-D-glucoside |
C21H20O11 |
448.38 |
C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O |
|
TCMBANKIN058229 |
daidzein |
Daidzei; 486-66-8; AIDS-059333; ST057515; KBio2_005871; CCRIS 7600; 7-Hydroxy-3-(4-hydroxy- phenyl)- chromone; SPBio_000205; AIDS059333; 4′,7-Dihydroxy- iso- flavone; nchembio.2007.28-comp31; KBio2_003303; Spectrum3_000191; Isoflavone, 4',7-dihydroxy- (8CI); Oprea1_182317; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; Spectrum5_000857; NCGC00025156-01; BiomolKI_000060; S00273; NCGC00015365-01; KBio1_001023; BiomolKI2_000066; KBioSS_000735; Daidzeol; SMP1_000089; 7,4'-Dihydroxyisoflavone; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; C10208; SPECTRUM200789; nchembio.76-comp16; BSPBio_001741; NCGC00025156-09; Daidzein (6CI); 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; BRN 0231523; 5-18-04-00089 (Beilstein Handbook Reference); Daidzein; Daidzein (4',7-Dihydroxyisoflavone); KBioGR_002432; NINDS_001023; KBio2_000735; ACon1_000543; NCGC00025156-07; ZINC00047551; daidzein ; NCGC00025156-02; Lopac-D-7802; Tocris-1417; 7-hydroxy-3-(4-hydroxyphenyl)chromone; ACon0_001477; 7-Hydroxy-3-(4-hydroxy-phenyl)-chromone; KBio3_001241; DivK1c_001023; Spectrum4_001964; K 251b; UPCMLD-DP052:001; IDI1_001023; MEGxm0_000123; Lopac0_000412; D7802_SIGMA; Spectrum2_000053; EINECS 207-635-4; Spectrum_000255; 4′,7-Dihydroxyisoflavone; NCGC00025156-05; 4',7-Dihydroxy-iso-flavone; NCGC00025156-04; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)-4-chromenone; 7-Hydroxy-3-(4-hydroxy- phenyl)-4H-1-benzo- pyran-4-one; EU-0100412; CHEBI:28197; SDCCGMLS-0066422.P001; 4',7-Dihydroxyisoflavone; Oprea1_305345 |
C15H10O4 |
254.24 |
C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O |
|
TCMBANKIN058230 |
kakonein |
puerarin;puerarin-4'-o-d-glucoside;8-(beta-D-Glucopyranosyl-7-hydroxy-3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one; NPI-31G; 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; SCHEMBL14329031; 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]-4-chromenone; 82435_FLUKA; daidzein 8-C-glucoside; Puerarin; P5555_SIGMA; 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; 3681-99-0; ANGC-3681-99-0; 8-(beta-D-Glucopyranosyl)-4',7-dihydroxyisoflavone; C10524; 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]chromone |
C21H20O9 |
416.4 g/mol |
C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3C4C(C(C(C(O4)CO)O)O)O)O)O |
|
TCMBANKIN058341 |
1,7-diphenylhept-4-en-3-one |
DAH-3-Keto-4-en;1,7-diphenyl-4-hepten-3-one;MEGxp0_001315; (4E)-1,7-diphenyl-hepta-4-en-3-on; ACon1_001294; InChI=1/C19H20O/c20-19(16-15-18-11-5-2-6-12-18)14-8-7-13-17-9-3-1-4-10-17/h1-6,8-12,14H,7,13,15-16H2/b14-8; (E)-1,7-di(phenyl)hept-4-en-3-one; 1,7-Diphenylhept-4-en-3-one |
C19H20O |
264.4 g/mol |
C1=CC=C(C=C1)CCC=CC(=O)CCC2=CC=CC=C2 |
|
TCMBANKIN058519 |
(-)-epigallocatechin-3-gallate; (-)-epigallocatechin 3-o-gallate;epigallocatechin gallate; galloyl-l-epigallocatechol; epigallocatechin 3-gallate; (-)-epigallocatechin gallate; |
KBio2_000796; SpecPlus_000277; 50299_FLUKA; Spectrum3_000244; KBioGR_002002; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] ester; MLS000758300; DivK1c_006373; (−)-Epigallocatechin gallate; EGCG; SPBio_000035; (−)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; KBioSS_000796; Epigallocatechin gallate; Spectrum4_001541; (-)-epigallocatechin 3-gallate; Tea catechin; AIDS000674; KBio2_005932; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromanyl] ester; KBio1_001317; 989-51-5; AIDS-000674; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); KBio2_003364; Galloyl-L-epigallocatechol; SDCCGMLS-0066550.P001; (-)-Epigallocatechol gallate; ACon1_001054; Spectrum5_000102; Green tea extract; MEGxp0_001166; C09731; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; (-)-Epigallocatechin gallate; CCRIS 3729; Teavigo; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Spectrum2_000168; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; (−)-cis-3,3′,4′,5,5′,7-Hexahydroxy-flavane-3-gallate; CHEBI:4806; (-)-epigallocatechin-3-gallate ; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; SPECTRUM210239; E4143_SIAL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; Spectrum_000316; (-)-EGCG; KBio3_001128; BSPBio_001628; Epigallocatechol, 3-gallate, (-)-; Epigallocatechin-3-gallate; E4268_SIAL; epigallocatechin gallate ; epigallocatechin-3-gallate; (-)epigallocatechin-3-gallate ; EGCG; 989E515; [5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate; HMS2051K21; CS-1258; AC1L22IG; AK165605; Green tea polyphenols, Anagen; (-)-Epigallocatechin-3-O-gallate, United States Pharmacopeia (USP) Reference Standard; AKOS015918182; CAS-989-51-5; Epigallocatechin gallate, primary pharmaceutical reference standard; W-5069; (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; (-)-Epigallocatechin gallate, analytical standard; Q-100914; DSSTox_RID_78830; AN-15867; DSSTox_GSID_29889; (-)-Epigallocatechol gallate; FT-0604392; NCGC00164319-04; Green tea extract; MEGxp0_001166; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; N1874; CHEBI:4806; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; BG00814299; HMS3649E08; D0E9DB; Epigallocatechol, 3-gallate, (-)-; (-)-EpigallocatechinGallateHydrate; Epigallocatechin-3-gallate; AB0014381; BQM438CTEL; NC00078; ST51055716; Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material; SpecPlus_000277; Spectrum3_000244; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl-3,4,5-trihydroxybenzoate; MLS000758300; (-)-Epigallocatechin gallate (EGCG); CCG-38378; Gallic acid, 3-ester with epigallocatechol, (-)-; SR-01000946601-1; NCGC00164319-01; (-)-cis-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1(2H)-benzopyran-3-yl Gallate; NCGC00164319-06; DSSTox_CID_567; MCULE-3341525983; Epigallocatechin monogallate, B; Tox21_303457; SAM001247031; 4awm; K791; 989-51-5; SR-01000946601; MFCD00075940; EGCG analogs; Galloyl-L-epigallocatechol; NCGC00164319-03; (-)-Epigallocatechin gallate, >=80% (HPLC), from green tea; Spectrum5_000102; CPD000449288; (-)-Epigallocatechin gallate; LMPK12030005; E0694; Teavigo; Epigallocatechin gallate analogs, Anagen; Epigallocatechin-3-monogallate; ACN-035233; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; Sunphenon; Epigallocatechin gallate(EGCG); s2250; PF-EGCg 90; 3,4-Dihydro-5,7-dihydroxy-2R-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3R-yl-3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; MLS001424000; (-)-EGCG; ZINC3870412; KBio2_000796; EGCG cpd; KBioGR_002002; Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-; EGCG, Anagen; NCGC00257243-01; Tox21_201468; L-Epigallocatechin gallate; cid_65064; SPBio_000035; BG01747388; Epigallocatechin gallate; KBioSS_000796; Spectrum4_001541; (-)-epigallocatechin 3-gallate; DB12116; EPIGALOCATECHIN GALLATE; ANTIOXIDANT MODEL (TRAMP) -EPIGALLOCATECHIN GALLATE; KBio2_005932; I14-7747; D0U2BH; MCULE-7760530136; 2kdh; Epigallocatechin gallate, Anagen; AOB2839; SDCCGMLS-0066550.P001; 863-65-0; FR-109; ST097428; ACon1_001054; LS-2197; CCRIS 3729; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Epigallocate; GTPL7002; BDBM50070942; C22H18O11; GTPs,Anagen; SCHEMBL35258; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; MolPort-001-741-358; DivK1c_006373; KB-206444; SR-01000759328; Teavigo;; EGCG; (-)-EPIGALLOCATECHIN GALLATE (GREEN TEA EXTRACT); HY-13653; (-)-Epigallocatechin gallate, >=95%; NCGC00259019-01; Tea catechin; DS-9030; SR-01000759328-6; SR-01000759328-5; KDH; AC1Q5X0Z; KBio1_001317; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxyb enzoate; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); NVP-XAA 723; KBio2_003364; EBD2138593; FT-0082796; NCGC00164319-02; C09731; (-)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; UNII-BQM438CTEL; DTXSID1029889; WMBWREPUVVBILR-WIYYLYMNSA-N; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; (-)-Epigallocatehin gallate; Spectrum2_000168; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; (-)-Epigallocatechin gallat; SPECTRUM210239; Epigallocic acid; Epigallocatcchin Gallate; KS-0000132O; BP-30205; CHEMBL297453; SC-47284; Spectrum_000316; 3oob; (-)-Epigallocatechin gallate, >=97.0% (HPLC); KBio3_001128; BSPBio_001628; epigallo-catechin gallate |
C22H18O11 |
458.4g/mol |
C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O |
|
TCMBANKIN058652 |
irilone |
9-hydroxy-7-(4-hydroxyphenyl)-8-pyrano[2,3-f][1,3]benzodioxolone; 41653-81-0; irolone; 9-hydroxy-7-(4-hydroxyphenyl)pyrano[2,3-f][1,3]benzodioxol-8-one; Irilone; C10467; Irolone |
C16H10O6 |
298.25 g/mol |
C1OC2=C(O1)C(=C3C(=C2)OC=C(C3=O)C4=CC=C(C=C4)O)O |
|
TCMBANKIN058805 |
Anhydroicaritin |
118525-40-9; anhydroicaritin; 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one; 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromone; 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-4-chromenone |
C21H20O6 |
368.38 |
CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC=C(C=C3)OC)O)C |
|
TCMBANKIN058858 |
ginsenoside- Rg1 |
ginsenoside-rg1;(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(1S)-1,5-dimethyl-1-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]hex-4-enyl]-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H; (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a; (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(1S)-1,5-dimethyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-hex-4-enyl]-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclop; (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[; C08946; (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(1S)-1,5-dimethyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-hex-4-enyl]-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-; 22427-39-0; sanchinoside rg1; Sanchinoside C1 |
C42H72O14 |
801.01 g/mol |
CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)O)C)O)C)OC6C(C(C(C(O6)CO)O)O)O)C |
|
TCMBANKIN058900 |
myrrhanol a |
myrrhanol C; myrrhanol B; Myrrhanol A |
C30H52O3 |
460.7 g/mol |
CC(=CCCC1C2(CCC(C(C2CCC1(C)O)(C)C)O)C)CCC=C(C)CCC=C(C)CO |
|
TCMBANKIN058945 |
Isoramanone |
ramanone isoramanone |
C21H32O4 |
348.48 |
CC(=O)C1CCC2(C1(C(CC3C2CC=C4C3(CCC(C4)O)C)O)C)O |
|
TCMBANKIN058948 |
PLO |
Prestwick_859; Delta5-Pregnen-3beta-ol-20-one; C01953; Pregnenolona [INN-Spanish]; Prestwick3_000546; LMST02030088; BPBio1_000651; P9129_SIGMA; 81630_FLUKA; 3beta-Hydroxy-5-pregnene-20-one; 3beta-hydroxypregn-5-ene-20-one; Prestwick0_000546; Pregn-5-en-20-one, 3beta-hydroxy-; 5-Pregnen-3-beta-ol-20-one; Prestwick1_000546; Pregn-5-en-20-one, 3beta-hydroxy- (8CI); 3beta-Hydroxy-5-pregnen-20-one; Pregnenolone (progesterone precursor); Prestwick2_000546; Pregnenolone (JAN/INN); Spectrum5_002057; 3beta-Hydroxypregn-5-en-20-one; CMC_13393; SPBio_002512; D00143; Pregn-5-en-20-one, 3-hydroxy-, (3-beta)-; Pregnenolonum [INN-Latin]; delta5-Pregnenolone; 3beta-Hydroxy-Delta5-pregnen-20-one; BSPBio_000591; CHEBI:16581; 5-Pregnen-3beta-ol-20-one; ZINC03861150; Pregn-5-en-20-one, 3-beta-hydroxy-; 3-beta-Hydroxypregn-5-en-20-one; Pregn-5-en-3beta-ol-20-one; Delta5-Pregnene-3beta-ol-20-one; PREGNENOLONE; ST5308463; (3BETA)-3-HYDROXYPREGN-5-EN-20-ONE; 5-Pregnenolone; 17beta-[1-Ketoethyl]-Delta5-androsten-3beta-ol; EINECS 205-647-4; 1-[(3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone; 145-13-1; NSC 1616; Pregn-5-ene-3beta-ol-20-one; 116907-59-6; Pregn-5-en-20-one, 3-hydroxy-, (3beta)- |
C21H32O2 |
316.5 g/mol |
CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
|
TCMBANKIN058990 |
forskolin |
coleonol |
C22H34O7 |
410.5 g/mol |
CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O |
|
TCMBANKIN059120 |
Ostreasterol |
(3S,8S,9S,10R,13R,14S,17R)-17-[(1R)-4-isopropyl-1-methyl-pent-4-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Ergosta-5,24(28)-dien-3beta-ol (8CI); (3S,8S,9S,10R,13R,14S,17R)-17-[(1R)-1,5-dimethyl-4-methylenehexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 24-methylene-cholest-5-en-3beta-ol; Ergosta-5,24(28)-dien-3beta-ol; NSC 232664; 24-Methylenecholesterol; LMST01030099; Ergosta-5,24(28)-dien-3-ol, (3beta)- (9CI); (3S,8S,9S,10R,13R,14S,17R)-17-[(1R)-1,5-dimethyl-4-methylene-hexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 474-63-5; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methyl-5-methylidene-heptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Chalinasterol |
C28H46O |
398.66 |
CC(C)C(=C)CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
|
TCMBANKIN059144 |
ergosta-4,6,8(14),22-tetraen-3-one |
ergosta-4,6,8(14),22,tetraen-3-one; AJ-54768; (22E)-Ergosta-4,6,8(14),22-tetren-3-one; (22e,24r)-ergosta-4,6,8(14),22-tetraen-3-one; MolPort-023-298-990; Ergosta-4,6,8(14),22-tetraen-3-one, (22E)-; Ergosta-4,6,8(14),22-tetraen-3-one; (1R,9AR,9BR,11AR)-1-[(2R,3E,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-9A,11A-DIMETHYL-1H,2H,3H,8H,9H,9BH,10H,11H-CYCLOPENTA[A]PHENANTHREN-7-ONE; CHEBI:69431; BG01104490; 19254-69-4; CHEMBL3588948; UNII-RI51Y55U8P; Ergone; (22E)-Ergosta-4,6,8(14),22-tetraen-3-one; AKOS022184779; SCHEMBL6365010; (9R,10R,13R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-1,2,9,11,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one; AK104269; AC1O5V9Q; 24-methylcholesta-4,6,8(14),22-tetraen-3-one; ZINC5761087; W2324; RI51Y55U8P; 27625-48-5; ergone; (9R,10R,13R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-1,2,9,11,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one; (9R,10R,13R,17R)-10,13-dimethyl-17-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-1,2,9,11,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one; 19254-69-4; Ergosta-4,6,8(14),22-tetraen-3-one, (22E)- |
C28H40O |
392.6 g/mol |
CC(C)C(C)C=CC(C)C1CCC2=C3C=CC4=CC(=O)CCC4(C3CCC12C)C |
|
TCMBANKIN059147 |
ergosterin |
ergosterol;24-Methylcholesta-5,7,22-trien-3beta-ol; 24alpha-Methyl-22E-dehydrocholestero; (3beta,22E)-Ergosta-5,7,22-trien-3-ol; (7S,9AR,11AR)-1-[(2R,3E,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-9A,11A-DIMETHYL-1H,2H,3H,3AH,6H,7H,8H,9H,9BH,10H,11H-CYCLOPENTA[A]PHENANTHREN-7-OL; 45480_FLUKA; (24R)-Ergosta-5,7,22-trien-3b-ol; MEGxm0_000450; Ergosterin; 24R-Methylcholesta-5,7,22E-trien-3b-ol; 57-87-4; Ergosterol; ergosta-5,7,22E-trien-3beta-ol; (3beta)-Ergosta-5,7,22-trien-3-ol; C01694; 5,7,22-Ergostatrien-3beta-ol; AIDS064232; E6510_SIGMA; Provitamin D2; (22E)-Ergosta-5,7,22-trien-3.beta.-ol; A831651; ergosta-5,7,22-trienol; ergosta-5,7,22-trien-3 beta-ol; 24R-Methylcholesta-5,7,22E-trien-3beta-ol; ACon0_000429; ERG; ST073383; (3S,10R,13R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; 24-Methylcholesta-5,7,22-trien-3b-ol; ACon1_000637; (3beta,2E)-Ergosta-5,7,22-trien-3-ol; Provitamine D2; AIDS-064232; 24a-Methyl-22E-dehydrocholesterol; ergosta-5,7,22-trien-3-ol; 47130U_SUPELCO; LMST01030093; (22E)-ergosta-5,7,22-trien-3beta-ol; ZINC04084618; (3S,9S,10R,13R,14R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; 3beta-Hydroxy-5,7,22-ergostatriene; CHEBI:16933; (3S,9S,10R,13R,14R,17R)-10,13-dimethyl-17-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; (22E,24S)-24-methylcholesta-5,7,22-trien-3beta-ol |
C28H44O |
396.6 g/mol |
CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2=CC=C4C3(CCC(C4)O)C)C |
|
TCMBANKIN059149 |
Ergosterol peroxide |
2061-64-5; NSC31324; Ergosterol peroxide; 5.alpha.,8.alpha.-Ergosta-6,22-dien-3.beta.-ol, 5,8-epidioxy-; ERGOSTEROL-5,8-PEROXIDE; Ergosterol 5.alpha.,8.alpha.-epidioxide; Ergosta-6,22-dien-3-ol, 5,8-epidioxy-, (3.beta.,5.alpha.,8.alpha.,22E)-; Ergosterol endoperoxide; (3β,5α,8α,22E,24R)-5,8-Epidioxyergosta-6,22-dien-3-ol; 5,8-epidioxyergosta-6,22-dien-3-ol; Peroxyergosterol; ergosterol peroxide; 2061-64-5; ergosterolperoxide; dimethyl-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl][?]ol; (3.beta.,5.alpha.,8.alpha.,22E)-5,8-Epidioxyergosta-6,22-dien-3-ol |
C28H44O3 |
428.6 g/mol |
CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C24C=CC5(C3(CCC(C5)O)C)OO4)C |
|
TCMBANKIN059168 |
Tryptophenolide |
KBio1_001606; KBio2_007338; KBio3_002756; Spectrum2_001618; KBio2_004770; KBio2_002202; Phenanthro(1,2-c)furan-1(3H)-one, 3b,4,5,9b,10,11-hexahydro-6-hydroxy-9b-methyl-7-(1-methylethyl)-, (3bR-trans)-; BSPBio_003528; SDCCGMLS-0066775.P001; hypolide; (3bR,9bS)-6-hydroxy-9b-methyl-7-propan-2-yl-3,3b,4,5,10,11-hexahydronaphtho[4,3-g][2]benzoxol-1-one; Spectrum4_001660; Spectrum5_000539; SPECTRUM1504005; DivK1c_006662; SPBio_001655; Triptophenolide; (3bR,9bS)-6-hydroxy-7-isopropyl-9b-methyl-3,3b,4,5,10,11-hexahydronaphtho[3,4-e]isobenzofuran-1-one; KBioGR_002159; Spectrum_001722; Spectrum3_001928; 74285-86-2; SpecPlus_000566; KBioSS_002202 |
C20H24O3 |
312.4 g/mol |
CC(C)C1=C(C2=C(C=C1)C3(CCC4=C(C3CC2)COC4=O)C)O |
|
TCMBANKIN059172 |
81827-74-9 |
(3bR,9bS)-9-hydroxy-7-isopropyl-6-methoxy-9b-methyl-3,3b,4,5,10,11-hexahydronaphtho[3,4-e]isobenzofuran-1-one; Phenanthro(1,2-c)furan-1(3H)-one, 3b,4,5,9b,10,11-hexahydro-9-hydroxy-6-methoxy-9b-methyl-7-(1-methylethyl)-, (3bR-trans)-; (3bR,9bS)-9-hydroxy-6-methoxy-9b-methyl-7-propan-2-yl-3,3b,4,5,10,11-hexahydronaphtho[4,3-g][2]benzoxol-1-one;AC1NSZ34; 9-hydroxy-6-methoxy-9b-methyl-7-propan-2-yl-3,3b,4,5,10,11-hexahydronaphtho[2,1-e][2]benzofuran-1-one;neotriptophenolide |
C21H26O4 |
342.43 |
CC(C)C1=CC(=C2C(=C1OC)CCC3C2(CCC4=C3COC4=O)C)O |
|
TCMBANKIN059195 |
(1S,5S)-1-isopropyl-4-methylenebicyclo[3.1.0]hexane |
(1S,5S)-1-isopropyl-4-methylene-bicyclo[3.1.0]hexane; (1S,5S)-4-methylidene-1-propan-2-ylbicyclo[3.1.0]hexane; (1S,5S)-4-methylidene-1-propan-2-yl-bicyclo[3.1.0]hexane |
C10H16 |
136.23 g/mol |
CC(C)C12CCC(=C)C1C2 |
|
TCMBANKIN059249 |
CLR |
5-Cholesten-3b-ol; Hydrocerin; 5:6-Cholesten-3beta-ol; 209124-38-9; Lidinite; 5:6-Cholesten-3.beta.-ol; Tegolan (VAN); C1231_SIGMA; 3-beta-Hydroxycholest-5-ene; Delta5-Cholesten-3beta-ol; C3292_SIGMA; (3H)-Cholesterol; 20808_RIEDEL; S5442_SIGMA; Cholest-5-en-3-ol, (3-.beta.)-; Super hartolan; Cholesterol (JP15/NF); AIDS338945; 5:6-Cholesten-3-ol; nchembio782-comp1; 3beta-Hydroxy-5-cholestene; delta(sup 5)-Cholesten-3-beta-ol; Dusoline; CHOLESTEROL; D00040; C00187; Provitamin D; Wool alcohols B. P.; Cholest-5-en-3-ol, (3beta)-; Synthetic cholesterol; Dythol; CMC_13392; HSDB 7106; 3beta-Hydroxycholest-5-ene; Cordulan; 5,6-Cholesten-3.beta.-ol; Cholest-5-en-3.beta.-ol; 57-88-5; Kathro; Dusoran; (3beta)-cholest-5-en-3-ol; WLN: L E5 B666 LUTJ A1 E1 FY1&3Y1&1 OQ; 3.beta.-Hydroxycholest-5-ene; 26740_FLUKA; Cholesterol base H; Cholest-5-en-3-ol (3beta)-, labeled with tritium; NCGC00159351-02; 80356-14-5; Cholest-5-en-3-ol, (3.beta.)-; Cholestrin; 5-Cholesten-3beta-ol; ZINC03875383; 218965-24-3; 26732_FLUKA; Cholesterin; C8667_SIGMA; 22243-67-0; Lidinit; Phospholipon & Cholesterol; CHEBI:16113; SyntheChol NS0 Supplement; NSC 8798; nchembio.77-comp1; AI3-03112; Lanol; Cholestrol; AIDS080405; Cholest-5-en-3-ol (3beta)-; 5-Cholesten-3.beta.-ol; SyntheChol; NSC8798; Cholesterol solution; Cholesterol [USAN:JAN]; Nimco cholesterol base H; C8503_SIGMA; BB_NC-0135; SMP1_000069; C3137_SIGMA; Cholesterine; 47127U_SUPELCO; Cholest-5-en-3-beta-ol; Nimco cholesterol base No. 712; AIDS-338945; Cholesteryl alcohol; C3045_SIGMA; 14606_FLUKA; Soya phospholipon & Cholesterol (2:1 molar ratio); AIDS-080405; LMST01010001; CCRIS 2834; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Cholest-5-en-3beta-ol; Cholesterol (TN); EINECS 200-353-2; Tegolan;cholesterol;8(14)-dehydrocholesterol; 177962-82-2; SCHEMBL5347436; cholesta-5,8(14)-dien-3beta-ol; DJNCIOAUQVURTQ-RQZUOROGSA-N |
C27H46O |
386.65 |
CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
|
TCMBANKIN059272 |
diisobutyl phthalate |
di-isobutyl phthalate;ST5405544; diisobutyl benzene-1,2-dicarboxylate; benzene-1,2-dicarboxylic acid diisobutyl ester; Di-iso-butyl phthalate; 80130_FLUKA; Isobutyl phthalate; bis(2-methylpropyl) benzene-1,2-dicarboxylate; (C4-C13) Branched alkyl alcohols, phthalic anhydride ester; ZINC00388318; EINECS 201-553-2; NSC15316; 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl) ester; Diisobutyl phthalate; 152641_ALDRICH; EINECS 273-157-8; 68951-39-3; C15205; AI3-04278; Phthalic acid, diisobutyl ester; BRN 2054802; NCGC00091360-01; NSC 15316; WLN: 1Y1&1OVR BVO1Y1&1; 4-09-00-03177 (Beilstein Handbook Reference); Diisobutylester kyseliny ftalove [Czech]; Hexaplas M/1B; 1,2-Benzenedicarboxylic acid, C4-13-branched alkyl esters; AI3-04278 (USDA); Kodaflex DIBP; 68955-80-6; Hatcol DIBP; HSDB 5247; CCRIS 6193; di-l-butyl phthalate (DIBP); Di(i-butyl)phthalate; SMR000112470; MLS000516002; 84-69-5; Palatinol IC |
C16H22O4- C6H4[CO2CH2CH(CH3)2]2 |
278.34 g/mol |
CC(C)COC(=O)C1=CC=CC=C1C(=O)OCC(C)C |
|
TCMBANKIN059284 |
delta 5-Pregnenetriol |
(3S,8R,9S,10R,13S,14S,17R)-17-(1-hydroxyethyl)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol; 903-67-3; 5-Pregnene-3beta,17alpha,20alpha-triol; Pregn-5-ene-3,17,20-triol, (3beta,20S)-; Pregn-5-ene-3beta,17alpha,20alpha-triol; 5-pregnene-3β,17α,20α-triol |
C21H34O3 |
334.49 |
CC(C1(CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)O)O |
|
TCMBANKIN059337 |
CHD;cholalic acid;cholicacid |
5beta-Cholanic acid, 3alpha,7alpha,12alpha-trihydroxy- (7CI); cholic acid; 3alpha,7alpha,12alpha-Trihydroxycholanic acid; 81-25-4 (FREE ACID); CHOLATE; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanoic acid; (3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxycholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-beta-cholanic acid; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; Colalin; C9377_SIGMA; SMR000112165; 3.alpha.,7.alpha.,12.alpha.-Trihydroxy-5.beta.-cholanic acid; AIDS017669; 5.beta.-Cholan-24-oic acid, 3.alpha.,7.alpha.,12.alpha.-trihydroxy-; MLS001066422; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)- (9CI); AIDS-017669; Cholic acid (8CI); Cholalic acid; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3-alpha,5-beta,7-alpha,12-alpha)-; Cholsaeure; C1129_SIGMA; ST024722; Spectrum5_002005; 5beta-Cholanic acid-3alpha,7alpha,12alpha-triol 5beta-Cholic acid; Cholalin; 17beta-[1-Methyl-3-carboxypropyl]etiocholane-3alpha,7alpha,12alpha-triol; 73163-53-8 (NA SALT); NSC-6135; 81-25-4; 3-&alpha,7-&alpha,12-&alpha-trihydroxy-5-&beta-cholanate; (3.alpha.,5.beta.,7.alpha.,12.alpha.)-3,7,12-Trihydroxycholan-24-oic acid sodium salt; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; NSC6135; CHEBI:16359; C00695; LMST04010001;cholic acid;cholic acid |
C24H40O5 |
408.57;408.6 g/mol |
CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C |
|
TCMBANKIN059340 |
5β-cholanicacid |
5 beta-cholanic acid; Cholanoic acid; 5.beta.-Cholanic acid; CHEBI:36238; Cholan-24-oic acid, (5beta)- (9CI); LMST04010441; Cholan-24-oic acid, (5.beta.)-; (4R)-4-[(5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; NSC18161; (4R)-4-[(5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; Ursocholanic acid; 5beta-Cholanoic acid; 5beta-Cholan-24-oic acid (8CI); NSC 18161; Androstane-17-butanoic acid, gamma-methyl-, (5beta,17beta)-; 5beta-Cholan-24-oic Acid; 5.beta.-Cholan-24-oic acid; L 596205-0; 5beta-Cholanic acid; Androstane-17-butanoic acid, .gamma.-methyl-, (5.beta.,17.beta.)-; (5beta)-cholan-24-oic acid; 546-18-9; 5.beta.-Cholanoic acid; (5beta,17beta)-gamma-methylandrostane-17-butanoic acid |
C24H40O2 |
360.57 |
CC(CCC(=O)O)C1CCC2C1(CCC3C2CCC4C3(CCCC4)C)C |
|
TCMBANKIN059352 |
lanosterol |
LAN; (3beta)-lanosta-8,24-dien-3-ol; L5768_SIGMA; ZINC03870056; ST5309405; CHEBI:16521; Lanosta-8,24-dienol; 79-63-0; LMST01010017; (3S,5R,10S,13R,14R,17R)-17-[(1R)-1,5-dimethylhex-4-enyl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; lanosta-8,24-dien-3beta-ol; (3beta,5alpha)-4,4,14-trimethylcholesta-8,24-dien-3-ol; Botalan base 138; (3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; Lanosta-8,24-dien-3-ol, (3.beta.)-; 4,4',14alpha-Trimethyl-5alpha-cholesta-8,24-dien-3beta-ol; 8,24-Lanostadien-3beta-ol; L1504_SIGMA; Cholesta-8,24-dien-3-ol, 4,4,14-trimethyl-, (3.beta.,5.alpha.)-; Lanster; C01724; NSC60677; LANOSTEROL; Lanosterin; 3beta-Hydroxy-8,24-lanostadiene; Lanosta-8,24-dien-3.beta.-ol |
C30H50O |
426.72 g/mol |
CC(CCC=C(C)C)C1CCC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)O)C)C)C |
|
TCMBANKIN059402 |
Sitosterol alpha1 |
|
C30H50O |
426.72 |
CC=C(CCC(C)C1CCC2C1(CCC3C2=CCC4C3(CCC(C4C)O)C)C)C(C)C |
|
TCMBANKIN059403 |
Fucosterol |
|
C29H48O |
412.7 g/mol |
CC=C(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN059404 |
Guggulsterone |
|
C21H28O2 |
312.45 |
CC=C1C(=O)CC2C1(CCC3C2CCC4=CC(=O)CCC34C)C |
|
TCMBANKIN059511 |
Benihinal |
|
C10H14O |
150.22 g/mol |
CC1(C2CC=C(C1C2)C=O)C |
|
TCMBANKIN059565 |
leonuridine |
|
C15H24O9 |
348.34 g/mol |
CC1(CC(C2C1C(OC=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O |
|
TCMBANKIN059602 |
δ-amyrenol |
|
C30H50O |
426.7 g/mol |
CC1(CCC2(CCC3(C(=C2C1)CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C)C)C |
|
TCMBANKIN059643 |
sandaracopimaric acid |
|
C20H30O2 |
302.5 g/mol |
CC1(CCC2C(=C1)CCC3C2(CCCC3(C)C(=O)O)C)C=C |
|
TCMBANKIN059645 |
isopimaric acid |
|
C20H30O2 |
302.5 g/mol |
CC1(CCC2C(=CCC3C2(CCCC3(C)C(=O)O)C)C1)C=C |
|
TCMBANKIN059758 |
triptinin a |
|
C21H28O3 |
328.45 g/mol |
CC1=C(CCC2(C1CCC3=C2C=CC(=C3OC)C(C)C)C)C(=O)O |
|
TCMBANKIN059842 |
o-Acetyl-p-cresol |
|
C9H10O2 |
150.17 g/mol |
CC1=CC(=C(C=C1)O)C(=O)C |
|
TCMBANKIN059901 |
p-xylene |
|
C8H10 |
106.17 |
CC1=CC=C(C=C1)C |
|
TCMBANKIN060104 |
paristerone |
|
C27H44O7 |
480.6 g/mol |
CC12CCC3C(=CC(=O)C4C3(CC(C(C4)O)O)C)C1(CCC2C(C)(C(CCC(C)(C)O)O)O)O |
|
TCMBANKIN060110 |
oestrone |
|
C18H22O2 |
270.4 g/mol |
CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)O |
|
TCMBANKIN060111 |
17alpha-estradiol |
|
C18H24O2 |
272.4 g/mol |
CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O |
|
TCMBANKIN060160 |
quercitrin |
|
C21H20O11 |
448.4 g/mol |
CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)O)O)O)O |
|
TCMBANKIN060183 |
ginsenoside- Re |
|
C48H82O18 |
947.15 |
CC1C(C(C(C(O1)OC2C(C(C(OC2OC3CC4(C(CC(C5C4(CCC5C(C)(CCC=C(C)C)OC6C(C(C(C(O6)CO)O)O)O)C)O)C7(C3C(C(CC7)O)(C)C)C)C)CO)O)O)O)O)O |
|
TCMBANKIN060311 |
gramisterol |
|
C29H48O |
412.69 g/mol |
CC1C(CCC2(C1CC=C3C2CCC4(C3CCC4C(C)CCC(=C)C(C)C)C)C)O |
|
TCMBANKIN060312 |
Lophenol |
|
C28H48O |
400.68 |
CC1C(CCC2(C1CC=C3C2CCC4(C3CCC4C(C)CCCC(C)C)C)C)O |
|
TCMBANKIN060313 |
epifriedelinol |
|
C30H52O |
428.73 g/mol |
CC1C(CCC2C1(CCC3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C)C)C)C)C)C)O |
|
TCMBANKIN060332 |
thujene |
|
C10H16 |
136.23 g/mol |
CC1C=CC2(C1C2)C(C)C |
|
TCMBANKIN060401 |
acetic acid [(1R,3R,4R,4aS,8aS)-4-hydroxy-3,4a,8,8-tetramethyl-4-[2-(5-oxo-2H-furan-3-yl)ethyl]-1-decalinyl] ester |
|
C22H34O5 |
378.5g/mol |
CC1CC(C2C(CCCC2(C1(CCC3=CC(=O)OC3)O)C)(C)C)OC(=O)C |
|
TCMBANKIN060512 |
smilagenin |
|
C27H44O3 |
416.6 g/mol |
CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)O)C)C)C)OC1 |
|
TCMBANKIN060529 |
Tormentic acid |
|
C30H48O5 |
488.7 g/mol |
CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)O)C)C)C2C1(C)O)C)C(=O)O |
|
TCMBANKIN060544 |
alpha-amyrin |
|
C30H50O |
426.72 g/mol |
CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1C)C)C |
|
TCMBANKIN060578 |
Solanidine |
|
C27H43NO |
397.6 g/mol |
CC1CCC2C(C3C(N2C1)CC4C3(CCC5C4CC=C6C5(CCC(C6)O)C)C)C |
|
TCMBANKIN060674 |
Δ7-stigmasterol |
|
C29H48O |
412.69 |
CCC(C=CC(C)C1CCC2C1(CCC3C2=CC=C4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN060675 |
stigmasta-7, 22-dien-3-one |
|
C29H46O |
410.7 g/mol |
CCC(C=CC(C)C1CCC2C1(CCC3C2=CCC4C3(CCC(=O)C4)C)C)C(C)C |
|
TCMBANKIN060676 |
bessisterol |
|
C29H48O |
412.7 g/mol |
CCC(C=CC(C)C1CCC2C1(CCC3C2=CCC4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN060682 |
delta22-Stigmasterol |
|
C29H50O |
414.79 |
CCC(C=CC(C)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN060683 |
delta7-Stigmastenone-3;7-stigmastenone-3 |
|
C29H48O |
412.69 |
CCC(CCC(C)C1CCC2C1(CCC3C2=CCC4C3(CCC(=O)C4)C)C)C(C)C |
|
TCMBANKIN060684 |
delta 7-stigmastenol |
|
C29H50O |
414.7 g/mol |
CCC(CCC(C)C1CCC2C1(CCC3C2=CCC4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN060686 |
7-oxo-β-sitosterol |
|
C29H48O2 |
428.7 g/mol |
CCC(CCC(C)C1CCC2C1(CCC3C2C(=O)C=C4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN060688 |
stigmastane-3,6-dione |
|
C29H48O2 |
428.69 |
CCC(CCC(C)C1CCC2C1(CCC3C2CC(=O)C4C3(CCC(=O)C4)C)C)C(C)C |
|
TCMBANKIN060691 |
poriferast-5-en-3beta-ol;22,23-dihydrostigmasterol;gamma-sitosterol;clionasterol;beta-dihydrofucosterol |
|
C29H50O |
414.71 g/mol |
CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN060693 |
Sitogluside |
|
C35H60O6 |
576.85g/mol |
CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC5C(C(C(C(O5)CO)O)O)O)C)C)C(C)C |
|
TCMBANKIN060694 |
24-Ethylcholest-4-en-3-one |
|
C29H48O |
412.69 |
CCC(CCC(C)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(C)C |
|
TCMBANKIN060695 |
24alpha-ethyl-5alpha-cholestan-3beta-ol |
|
C29H52O |
416.72 |
CCC(CCC(C)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C)C(C)C |
|
TCMBANKIN060785 |
Levistolid A |
|
C24H28O4 |
380.48 |
CCCC=C1C2=C(C3C(CC2)C4CCC35C(=C4)C(=O)OC5=CCCC)C(=O)O1 |
|
TCMBANKIN060838 |
Caproate;Butyl acetate |
|
C6H11O2- |
115.15 g/mol |
CCCCCC(=O)[O-] |
|
TCMBANKIN060942 |
nonane |
|
C9H20 |
128.26 |
CCCCCCCCC |
|
TCMBANKIN060958 |
oleic acid;cis-oleic acid;oleinic acid |
|
C18H34O2 |
282.46 |
CCCCCCCCC=CCCCCCCCC(=O)O |
|
TCMBANKIN061011 |
1-tridecene; Tridecylene; tridecene |
|
C13H26 |
182.35 |
CCCCCCCCCCCC=C |
|
TCMBANKIN061032 |
phorbol 12-myristate 13-acetate |
|
C8H8HgO2 |
616.8 g/mol |
CCCCCCCCCCCCCC(=O)OC1C(C2(C(C=C(CC3(C2C=C(C3=O)C)O)CO)C4C1(C4(C)C)OC(=O)C)O)C |
|
TCMBANKIN061091 |
stearic acid |
|
CH3(CH2)16COOH |
284.5 g/mol |
CCCCCCCCCCCCCCCCCC(=O)O |
|
TCMBANKIN061571 |
curcumin ii |
demethoxycurrcumin;24939-17-1; D03EDF; AC1NV635; SCHEMBL2553051; Demethoxycurcumin; CHEBI:65737; X1121; 33171-16-3; (1E,6E)-1-(4-Hydroxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; (1E,6E)-1-(4-HYDROXY-3-METHOXY-PHENYL)-7-(4-HYDROXYPHENYL)HEPTA-1,6-DIENE-3,5-DIONE; AK198734; 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; monodemethoxycurcumin; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-hepta-1,6-diene-3,5-dione; (2E)-Demethoxy Curcumin; BHCFM; feruloyl-p-coumaroylmethane; CS-3738; (1E,4Z,6E)-5-Hydroxy-1-(4-hydroxy-3-methoxy-phenyl)-7-(4-hydroxy-phenyl)-hepta-1,4,6-trien-3-one; Demethoxycurcumin, >=98% (HPLC); 1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; Feruloyl-P-hydroxycinnnamoylmethane; cid_5324476; NSC-687841; 9331AF; W2F8059T80; p-hydroxycinnamoylferuloylmethane; demethoxy-curcumin; 4-hydroxycinnamoyl(feruloyl)methane; AKOS015903509; 1-(4-Hydroxy-3-methoxyphenyl)-7-(p-hydroxyphenyl)-1,6-heptadiene-3,5-dione; 22608-11-3; 1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione, 9CI; p-Hydroxycinnamoylferuloylmethane; ZINC5115722; UNII-W2F8059T80; BDBM50163744; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; N1720; MolPort-016-638-373; 4-Hydroxycinnamoyl(feroyl)methane; 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)- (VAN); 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-, (1E,6E)-; HY-N0006; BG01626458; Q-100287; I14-18646; curcuminII; MolPort-044-724-513; 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-; NSC687841; 5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one; 1281950-91-1; Ambap22608-11-3; 85801-93-0; (E,E)-1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; 1-(4-Hydroxystyryl)-3-(3-methoxy-4-hydroxystyryl)propanedial; SCHEMBL431246; Demethoxycurcumin, analytical standard; (1E,6E)-1-(4-Hydroxy-3-methoxy-phenyl)-7-(4-hydroxy-phenyl)-hepta-1,6-diene-3,5-dione; demethoxycurrcumin; AK544533; MFCD03427310; SCHEMBL13521973;24939-17-1; D03EDF; AC1NV635; SCHEMBL2553051; Demethoxycurcumin; CHEBI:65737; X1121; 33171-16-3; (1E,6E)-1-(4-Hydroxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; (1E,6E)-1-(4-HYDROXY-3-METHOXY-PHENYL)-7-(4-HYDROXYPHENYL)HEPTA-1,6-DIENE-3,5-DIONE; AK198734; demethoxy curcumin; 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; monodemethoxycurcumin; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-hepta-1,6-diene-3,5-dione; (2E)-Demethoxy Curcumin; BHCFM; feruloyl-p-coumaroylmethane; CS-3738; (1E,4Z,6E)-5-Hydroxy-1-(4-hydroxy-3-methoxy-phenyl)-7-(4-hydroxy-phenyl)-hepta-1,4,6-trien-3-one; Demethoxycurcumin, >=98% (HPLC); 1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; Feruloyl-P-hydroxycinnnamoylmethane; cid_5324476; NSC-687841; 9331AF; W2F8059T80; AIDS110025; demethoxy-curcumin; (1E,6E)-1-(4-hydroxy-3-methoxy-phenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; 4-hydroxycinnamoyl(feruloyl)methane; AKOS015903509; 1-(4-Hydroxy-3-methoxyphenyl)-7-(p-hydroxyphenyl)-1,6-heptadiene-3,5-dione; 22608-11-3; 1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione, 9CI; p-Hydroxycinnamoylferuloylmethane; ZINC5115722; UNII-W2F8059T80; 1-(4-hydroxy-3-methoxy-phenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; BDBM50163744; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; N1720; MolPort-016-638-373; 4-Hydroxycinnamoyl(feroyl)methane; 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)- (VAN); 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-, (1E,6E)-; HY-N0006; BG01626458; Q-100287; I14-18646; curcuminII; MolPort-044-724-513; 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-; NSC687841; 5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one; 1281950-91-1; Ambap22608-11-3; 85801-93-0; (E,E)-1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; 1-(4-Hydroxystyryl)-3-(3-methoxy-4-hydroxystyryl)propanedial; SCHEMBL431246; Demethoxycurcumin, analytical standard; (1E,6E)-1-(4-Hydroxy-3-methoxy-phenyl)-7-(4-hydroxy-phenyl)-hepta-1,6-diene-3,5-dione; AIDS-110025; AK544533; MFCD03427310; SCHEMBL13521973;demethoxycurcumin |
C20H18O5 |
338.35 |
COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC=C(C=C2)O)O |
|
TCMBANKIN061590 |
isorhamnetin |
3'-O-Methylquercetin; 3,5,7-trihydroxy-2-(4-hydroxy-3-methoxy-phenyl)chromone; 3,5,7-trihydroxy-2-(4-hydroxy-3-methoxy-phenyl)chromen-4-one; Isorhamnetin; BRN 0044723; Flavone, 3,3',5,7-tetrahydroxy-4'-methoxy-; C10084; Quercetin 3'-methyl ether; 3'-Methoxyquercetin; CCRIS 3791; 3,5,7-Trihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)- (9CI); C.I. 75680; 4'-Methoxy-3,3',5,7-tetrahydroxy-flavone; ST5309356; Quercetin, 4'-methyl ether; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; AIDS-003060; 480-19-3; ACon1_000275; AIDS003060; 4'-O-Methylquercetin; 3-Methylquercetin; Oprea1_145406; ZINC00517261; 4'-Methoxyquercetin; NCGC00163572-01; 3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one; BRN 0324993; 4H-1-Benzopyran-4-one, 2-(3-methoxy-4-hydroxyphenyl)-3,5,7-trihydroxy-; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl)- (9CI); EINECS 210-050-7; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; MEGxp0_001863; NCGC00163572-02; EINECS 207-545-5; Isorhamnetol; 3,5,7-Trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 17794_FLUKA; FLAVONE, 4'-METHOXY-3,3',5,7-TETRAHYDROXY-; 4'-Methylquercetin; 5-18-05-00496 (Beilstein Handbook Reference); 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; 3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-chromenone; 3-Methylquercetine; FLAVONE, 3,4',5,7-TETRAHYDROXY-3'-METHOXY-; 3-methylquercetin; quercetin-3'-methyl ether |
C16H12O7 |
316.26 g/mol |
COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O |
|
TCMBANKIN061784 |
lirioresinol b dimethyl ether |
1H,3H-Furo(3,4-c)furan, tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-, (1S,3aR,4S,6aR)-; C24H30O8; ( )-O,O-Dimethyllirioresinol B; 1H,3H-Furo(3,4-c)furan, 3aalpha,4,6,6aalpha-tetrahydro-1alpha,4alpha-bis(3,4,5-trimethoxyphenyl)-; ( )-Yangabin; Yangabin; 1H,3H-Furo(3,4-c)furan, tetrahydro-1,4-bis(3,4,5)-trimethoxyphenyl)-, 1alpha,3aalpha,4alpha,6aalpha)-; CCRIS 8944; Lirioresinol B dimethyl ether; O,O-Dimethyllirioresinol B; lirioresinol b dimethyl-ether; Lirioresinol B, dimethyl-; LS-70759; (1S-(1alpha,3aalpha,4alpha,6aalpha))-isomer of epiyangambin; Lirioresinol B, O,O-dimethyl-; (- )-lirioresinol B; ACon1_001856; (1R,3aR,4S,6aR)-1,4-bis(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan; MEGxp0_001363; CTK4E6827; DTXSID10175733; SCHEMBL17385618; AC1L4ZYE; (1r,3ar,4r,6ar)-1,4-bis(3,4,5-trimethoxyphenyl)tetrahydro-1h,3h-furo[3,4-c]furan; 1H,3H-Furo(3,4-c)furan, tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-,(1R,3aR,4R,6aR)-; Diayangambin; (+)-Diayangambin; AC1Q70YI; (3R,3aR,6R,6aR)-3,6-bis(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan; Tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-(1R)-1alpha,3abeta,4alpha,6abeta-1H,3H-furo(3,4-c)furan; 21453-68-9; ZINC31477287; yangambin; C10894; ZINC04098936; (1S,3aR,4S,6aR)-1,4-bis(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan; 13060-14-5; Yangambin; diayangambin |
C24H30O8 |
446.5 g/mol |
COC1=CC(=CC(=C1OC)OC)C2C3COC(C3CO2)C4=CC(=C(C(=C4)OC)OC)OC |
|
TCMBANKIN061806 |
aristolochicacid iva |
aristolochic acid Ⅳa; aristolochic acid D;Aristoloside_qt |
C17H11NO8 |
357.27g/mol |
COC1=CC(=CC2=C3C(=C(C=C12)[N+](=O)[O-])C(=CC4=C3OCO4)C(=O)O)O |
滇IICP备16009434号-1 |
Dai SX Lab